META-ANALYSIS

Association between diabetes mellitus and tinnitus: A meta-analysis

Shi Luo¹, Jianxue Wen¹, Qilong Bao¹, Haibo Ou², Shuting Yi¹, and Peng Peng ^{1*}

Diabetes mellitus (DM) has been suggested as a potential risk factor for tinnitus, but evidence remains inconclusive. This meta-analysis aimed to evaluate the association between DM and tinnitus by systematically reviewing and synthesizing data from observational studies. A comprehensive literature search was conducted in PubMed, Embase, and Web of Science up to August 16, 2024. Observational studies with a sample size of at least 100 participants that assessed the relationship between DM and tinnitus were included. Studies involving populations with specific diseases were excluded. Odds ratios (ORs) and 95% confidence intervals (CIs) were pooled using a random-effects model. Study quality was assessed using the Newcastle-Ottawa Scale (NOS), and sensitivity and subgroup analyses were performed. Publication bias was evaluated using funnel plots and Egger's regression test. Twelve studies comprising 2,277,719 participants were included. The pooled analysis revealed a significant association between DM and tinnitus (OR: 1.18, 95% CI: 1.06–1.31, P = 0.002), with moderate heterogeneity ($I^2 = 51\%$). Sensitivity analyses confirmed the robustness of these findings. Subgroup analyses showed no significant differences by geographical region, mean age, sex distribution, tinnitus diagnosis method, or model used for association estimation. Publication bias was not detected (Egger's test P = 0.29). These findings suggest that DM is significantly associated with an increased risk of tinnitus. Further research is warranted to explore underlying mechanisms and causal relationships. Nonetheless, the results underscore the importance of monitoring tinnitus in patients with diabetes.

Keywords: Tinnitus, diabetes mellitus, DM, prevalence, risk factor, meta-analysis.

Introduction

Tinnitus, the perception of sound without an external source, is a common auditory condition affecting a significant portion of the global population [1, 2]. Epidemiological studies estimate that 10%-15% of adults experience chronic tinnitus, with prevalence rising with age and reaching up to 30% in elderly individuals [1, 3]. The condition can severely impair quality of life, causing disturbances in sleep, concentration, emotional well-being, and even leading to mental health issues, such as anxiety and depression [4, 5]. While some individuals adapt to tinnitus, others suffer from a persistent, debilitating form that disrupts daily functioning [6, 7]. Given its widespread prevalence and potential severity, understanding the risk factors for tinnitus is critical for developing effective prevention and management strategies. The etiology of tinnitus is multifactorial, involving a complex interplay of genetic, environmental, and medical factors [8,9]. Established risk factors include hearing loss, noise exposure, ototoxic medications, head and neck trauma, and psychological stress [10]. Additionally, metabolic and cardiovascular conditions, such as hypertension and dyslipidemia, have been implicated [11]. However, these factors alone do not fully account for the variability in tinnitus prevalence and severity, underscoring the need to identify

additional modifiable risk factors. One emerging area of interest is the role of systemic conditions, such as diabetes mellitus (DM), in the pathophysiology of tinnitus [12]. DM, a chronic metabolic disorder characterized by hyperglycemia, is associated with various microvascular and neural complications, raising questions about its potential impact on auditory dysfunction, including tinnitus [13]. The biological mechanisms linking DM to tinnitus remain unclear, but several pathways have been proposed. Hyperglycemia can induce oxidative stress and inflammation, which may impair cochlear function and damage auditory pathways [14]. Microvascular damage-a hallmark of DM-could reduce blood flow to auditory structures, further contributing to tinnitus [12]. Neuropathy, another common DM complication, may affect the auditory nerve, resulting in sensory dysfunction. Additionally, insulin resistance and glucose dysregulation might alter neurotransmitter activity, exacerbating tinnitus symptoms [13, 15]. Despite these plausible mechanisms, the relationship between DM and tinnitus remains under-researched, with inconsistent findings from existing studies [16-27]. While some studies report a significant association between DM and tinnitus [17, 18, 20, 21, 23], others find no correlation between DM and auditory function [16, 19, 22, 24-27]. These discrepan-

¹Department of Otorhinolaryngology and Head and Neck Surgery, The Affiliated Zhuzhou Hospital Xiangya Medical College CSU, Zhuzhou, China; ²Department of Otorhinolaryngology and Head and Neck Surgery, Xiangya Second Hospital of Central South University, Changsha, China.

^{*}Correspondence to Peng Peng: ppeng_zzuh@hotmail.com

DOI: 10.17305/bb.2024.11634

^{© 2025} Luo et al. This article is available under a Creative Commons License (Attribution 4.0 International, as described at https://creativecommons.org/licenses/by/4.0/).

cies highlight the need for a comprehensive evaluation of the evidence. To address this gap, we conducted a meta-analysis to synthesize current findings, assess the strength of the association between DM and tinnitus, and explore potential sources of heterogeneity across studies. By summarizing observational study results, this analysis aims to enhance our understanding of tinnitus etiology and guide future research and clinical practices in this area.

Materials and methods

This meta-analysis was conducted following the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) guidelines [28] and the Cochrane Handbook for Systematic Reviews and Meta-analysis [29]. The study protocol has been registered in PROSPERO under the identifier CRD42024594905.

Literature search

A comprehensive literature search was conducted across the PubMed, Embase, and Web of Science databases to identify studies published up to August 16, 2024, that evaluated the association between DM and tinnitus. The search strategy utilized terms related to "diabetes," "diabetes mellitus," and "tinnitus." Detailed search strategies for each database are provided in Supplemental data. Only studies published in peer-reviewed journals as full-length articles in English or Chinese were included. Additionally, as part of the manual screening process, the references of relevant original and review articles were reviewed to identify potential additional studies.

Inclusion and exclusion criteria

Eligible studies met the following inclusion criteria according to the PICOS principle were included.

Population (P): Studies including individuals with and without DM.

Intervention/Exposure (I): Presence of DM.

Comparison (C): Absence of DM.

Outcome (O): Reported association between DM and tinnitus, with sufficient data to calculate odds ratios (ORs) and 95% confidence intervals (CIs).

Study design (S): Observational studies (cohort, casecontrol, or cross-sectional) with a minimum sample size of 100 participants. We included studies with a minimum sample size of 100 participants to enhance the reliability of our findings. Smaller studies are more prone to variability and biases, such as publication bias and confounding effects, which could undermine the robustness of pooled estimates [30]. Evidence from meta-analytic methodology indicates that underpowered or small-sample studies may inflate effect sizes or lead to imprecise conclusions [30].

Studies involving populations with specific diseases (e.g., cardiovascular, neurological, or renal diseases) were excluded to minimize confounding effects. Additionally, reviews, case reports, editorials, and animal studies were not included. For overlapping patient populations, the study with the largest sample size was chosen for inclusion in the meta-analysis.

Data extraction

Two independent reviewers screened the titles, abstracts, and full texts of the studies and extracted relevant data using a standardized data extraction form. Discrepancies were resolved through discussion or consultation with a third reviewer. Extracted data included study characteristics (e.g., author, year of publication, country, and study design), participant characteristics (e.g., source of the population, sample size, age, and gender distribution), methods for diagnosing DM, type of DM, number of patients with DM, methods for validating tinnitus cases, number of patients with tinnitus, and confounders adjusted for when estimating the association between DM and tinnitus. If multiple effect estimates were reported, the most fully adjusted model was extracted.

Quality assessment

The quality of the included studies was assessed using the Newcastle-Ottawa Scale (NOS), which evaluates three domains: the selection of study groups, the comparability of groups, and the ascertainment of outcomes [31]. Each study received a score ranging from 0 to 9 stars, with studies scoring 6 stars or more classified as moderate-to-high quality. The risk of bias was independently evaluated by two reviewers, with disagreements resolved through discussion. Studies identified as having a high risk of bias were further analyzed through sensitivity analysis.

Statistical analysis

OR with 95% CI were calculated to examine the association between DM and tinnitus. The OR data and corresponding SE were derived from either the reported 95% CI or P values. These values were then logarithmically transformed to stabilize variance and normalize the distribution [29]. Statistical heterogeneity was assessed using the I^2 statistic, where values of 25%, 50%, and 75% indicate low, moderate, and high heterogeneity, respectively [32]. Given the variability in the included studies—such as differences in population characteristics, diabetes type, and tinnitus diagnosis methodssignificant clinical heterogeneity was identified. Therefore, the meta-analysis was conducted using the inverse variance (IV) method with a random-effects model to account for potential heterogeneity [29]. Sensitivity analyses were performed by excluding one study at a time, as well as by removing studies with lower NOS scores (<6) and those contributing to heterogeneity [33]. Subgroup analyses were conducted to explore the influence of study characteristics, including geographical region, mean age, sex distribution, tinnitus diagnosis methods, tinnitus prevalence, and the analytical model used (univariate or multivariate). The medians of continuous variables were used as cutoff values to define subgroups. Potential publication bias was evaluated using funnel plots, and Egger's regression test was employed to detect small-study effects [34]. A P value of less than 0.05 in Egger's test was considered indicative of publication bias. Statistical analyses were performed using RevMan (Version 5.1; Cochrane Collaboration, Oxford, UK) and Stata software (Version 17.0; Stata Corporation, College Station, TX).




Figure 1. PRISMA flowchart of study inclusion. DM: Diabetes mellitus.

Results

Literature search and study identification

The initial search across the three databases yielded 1043 records. After duplicate removal, 645 unique articles remained. Title and abstract screening narrowed these down to 28 studies for full-text review. Ultimately, 12 studies met the inclusion criteria, encompassing a total of 2,277,719 participants aged 16–27. A detailed PRISMA flow diagram is shown in Figure 1.

Study characteristics

The characteristics of the included studies are summarized in Table 1. These studies were published between 2015 and 2024 and conducted in Italy, China, the United States, Taiwan, the Netherlands, Brazil, and Korea. The study designs included two case-control studies [16, 26] and ten cross-sectional studies [17–25, 27]. Seven studies included participants from the general community population [20–22, 24–27], two studies involved individuals visiting Otolaryngology or Audiology

Clinics [16, 18], and three studies included participants undergoing health check-ups [17, 19, 23]. The mean ages of the participants ranged from 38.4 to 72.1 years, and the proportions of men ranged from 0% to 64.2%. The diagnosis of DM was confirmed by medical history in 11 studies [16–24, 26, 27] and by International Classification of Disease (ICD) codes in one study [25]. Most studies assessed the influence of overall DM (type 1 and/or type 2 DM) [16, 17, 19–27], while one study specifically evaluated the influence of type 2 DM (T2DM) on the prevalence of tinnitus [18]. Tinnitus validation methods varied across studies. Five studies used clinical diagnosis [16-19, 22], six studies relied on self-reported tinnitus symptoms [20, 21, 23, 24, 26, 27], and one study used ICD codes [25]. Overall, 552,247 participants (24.2%) were identified as having tinnitus. When examining the association between DM and tinnitus, univariate analyses were employed in four studies [20, 25–27], while multivariate analyses were used in the remaining eight studies [16-19, 21-24], adjusting for at least age and sex.

Study	Location	Study design	Participant characteristics	Sample size	Mean age (years)	Men (%)	Methods for diagnosis of DM	Type of DM	No. of participants with DM	Methods for diagnosis of tinnitus	Number of patients with tinnitus	Adjusted/matched variables
Martines, 2015	Italy	СС	Subjects visiting an audiology department	120	57.6	64.2	Medical history	T1DM or T2DM	14	Clinical diagnosis	46	Age and sex
Hong, 2016	China	CS	Participants of health check	1596	48.1	46.9	Medical history	T1DM or T2DM	NR	Clinical diagnosis	300	Age, sex, BMI, and comorbidities
Li, 2018	China	S	Subjects visiting an otolaryngology department	149	55.1	56.1	Medical history	T2DM	51	Clinical diagnosis	58	Age, sex, and BMI
Staudt, 2019	USA	CS	Community population aged 20–59 years	2511	38.4	47.8	Medical history	T1DM or T2DM	125	Self-reported symptom of tinnitus	589	None
Chang, 2019	Taiwan	S	Participants of health check aged 65 years or older	597	72.1	53.9	Medical history	T1DM or T2DM	123	Clinical diagnosis	191	Age and sex
Qian, 2020	USA	CS	Community population aged 20–69 years	2705	54.3	49.7	Medical history	T1DM or T2DM	510	Clinical diagnosis	499	Age, sex, hearing loss, noise exposure, and comorbidities
Loiselle, 2020	The Nether- lands	CS	Community population aged 25– 49 years	72709	49.9	40.4	Medical history	T1DM or T2DM	NR	Self-reported symptom of tinnitus	2944	Age, sex, hearing loss, BMI, and comorbidities
Chamouton, 2021	Brazil	CS	People visiting a healthcare service	1569	59.2	41.7	Medical history	T1DM or T2DM	NR	Self-reported symptom of tinnitus	496	Age, sex, comorbidities, and concurrent medications
Choi, 2021	Korea	CS	Community population	12537	38.9	52.5	Medical history	T1DM or T2DM	486	Self-reported symptom of tinnitus	2221	Age, sex, comorbidities, and depressive symptoms
Kuang, 2022	Taiwan	CS	Community population aged 18 years or older	2170728	55.1	42.8	ICD codes	T1DM or T2DM	450648	ICD codes	542682	None
Zeleznik, 2023	USA	CC	Community women aged 30–55 years	6477	52	0	Medical history	T1DM or T2DM	975	Self-reported symptom of tinnitus	488	None
Lee, 2024	Korea	CS	Community population aged 60 years or older	6021	69.3	48.9	Medical history	T1DM or T2DM	1215	Self-reported symptom of tinnitus	1733	None

Biomolecules & Biomedicine

4

Table 2.	Study quality evaluation via the Newcastle-Ottawa scale
----------	---

Study	Adequate definition of cases	Representa- tiveness of cases	Selection of con- trols	Definition of con- trols	Control for age and sex	Control for other con- founders	Exposure ascertain- ment	Same methods for events ascertainment	Non- response rates	Total
Martines, 2015	1	0	1	1	1	0	1	1	1	7
Hong, 2016	1	0	1	1	1	1	1	1	1	8
Li, 2018	1	0	1	1	1	1	1	1	1	8
Staudt, 2019	0	1	1	1	0	0	1	1	1	6
Chang, 2019	1	1	1	1	1	0	1	1	1	8
Qian, 2020	1	1	1	1	1	1	1	1	1	9
Loiselle, 2020	0	0	1	1	1	1	1	1	1	7
Chamouton, 2021	0	0	1	1	1	1	1	1	1	7
Choi, 2021	0	1	1	1	1	1	1	1	1	8
Kuang, 2022	0	1	1	1	0	0	0	1	1	5
Zeleznik, 2023	0	1	1	1	0	0	1	1	1	6
Lee, 2024	0	1	1	1	0	0	1	1	1	6

Risk of bias

Detailed study quality evaluation via the NOS score is shown in Table 2. The quality assessment using the NOS revealed that 11 studies scored 6 stars or more [16–24, 26, 27], indicating moderate to high quality. Most studies were rated favorably regarding selection criteria; however, comparability between groups and outcome assessment exhibited greater variability. Notably, some studies lacked adequate control for confounding variables, thereby increasing the potential for bias [20, 25–27]. Despite these limitations, all studies were included in the primary analysis.

Meta-analysis results

The meta-analysis demonstrated a significant association between DM and tinnitus (OR: 1.18, 95% CI: 1.06–1.31, P = 0.002; Figure 2). Moderate between-study heterogeneity was detected $(I^2 = 51\%)$, indicating some variability in effect estimates. A sensitivity analysis, performed by excluding one study at a time, showed consistent results (OR: 1.12–1.23, P all < 0.05). Specifically, excluding the only study [18] that evaluated the influence of T2DM yielded similar findings (OR: 1.16, 95% CI: 1.05–1.27, P = 0.003; $I^2 = 46\%$). Similarly, excluding the single study with a NOS score of five also produced consistent results (OR: 1.21, 95% CI: 1.07–1.38, P = 0.003; $I^2 = 55\%$). These results suggest that the findings are robust and not overly influenced by the inclusion of lower-quality studies or outliers with extreme effect sizes. Subsequent subgroup analyses indicated that the association between DM and tinnitus was not significantly impacted by various study characteristics. These included the study location (*P* for subgroup difference = 0.67; Figure 3A), mean participant age (P = 0.79; Figure 3B), proportion of male participants (P = 0.11; Figure 4A), tinnitus diagnosis methods (P = 0.17; Figure 4B), tinnitus prevalence within studies (P = 0.79; Figure 5A), and the statistical models used to estimate the association (P = 0.19; Figure 5B).

Publication bias

The funnel plots for the meta-analysis examining the association between diabetes and tinnitus are presented in Figure 6. A visual assessment of the funnel plot indicated no notable asymmetry, a finding corroborated by Egger's regression test, which showed no evidence of significant publication bias (P = 0.29). These results imply a low probability of small-study effects or selective reporting, thereby strengthening the reliability of the meta-analysis findings.

Discussion

The findings of this meta-analysis suggest a significant association between DM and tinnitus, with a pooled OR of 1.18, indicating that individuals with DM have an 18% higher likelihood of experiencing tinnitus compared to non-diabetic individuals. This association remained consistent across various sensitivity analyses, which excluded lower-quality studies and those contributing to heterogeneity. The consistent results reinforce the robustness of the association and suggest that DM may indeed be a risk factor for tinnitus. Previous studies have reported a range of ORs in examining this relationship, but our meta-analysis provides a more comprehensive conclusion by encompassing data from multiple studies with a large number of participants. Several biological mechanisms may underlie the relationship between DM and tinnitus. DM is characterized by chronic hyperglycemia, which can lead to microvascular and macrovascular complications, including damage to the auditory pathways [35, 36]. The cochlea, which has a high metabolic demand, may be particularly vulnerable to DM-related vascular damage. Chronic hyperglycemia can reduce blood flow to the inner ear, leading to ischemic damage and contributing to tinnitus [37]. Tinnitus may also arise from neuroplastic changes in the dorsal cochlear nucleus (DCN), where hyperglycemia-induced oxidative stress and

Biomolecules & Biomedicine

				Odds Ratio	C	Odds Ratio	
Study or Subgroup	log[Odds Ratio]	SE	Weight	IV, Random, 95% CI	IV, R	<u>andom, 95% C</u>	:
Martines 2015	0.54232429	0.57141569	0.8%	1.72 [0.56, 5.27]	-	•	
Hong 2016	0.55961579	0.1695785	6.8%	1.75 [1.26, 2.44]			
Li 2018	0.99694864	0.45669817	1.3%	2.71 [1.11, 6.63]			
Staudt 2019	0.37156356	0.20042616	5.3%	1.45 [0.98, 2.15]		-	
Chang 2019	-0.02020271	0.21728373	4.7%	0.98 [0.64, 1.50]		—	
Qian 2020	0.10436002	0.29749246	2.7%	1.11 [0.62, 1.99]		_ <u>-</u>	
Loiselle 2020	0.05826891	0.03598944	20.8%	1.06 [0.99, 1.14]		•	
Chamouton 2021	0.47623418	0.16673	6.9%	1.61 [1.16, 2.23]			
Choi 2021	0.06765865	0.16668542	6.9%	1.07 [0.77, 1.48]			
Kuang 2022	0.0861777	0.0700094	16.3%	1.09 [0.95, 1.25]		!	
Zeleznik 2023	0.19062036	0.11290022	11.2%	1.21 [0.97, 1.51]			
Lee 2024	0.01980263	0.06977999	16.4%	1.02 [0.89, 1.17]		+	
Total (95% CI)			100.0%	1.18 [1.06, 1.31]		♦	
Heterogeneity: Tau ² = 0 Test for overall effect: 2			.02); l² = 5	51%	0.2 0.5	1 2	<u> </u> 5

Figure 2. Forest plots for the meta-analysis of the association between DM and tinnitus. DM: Diabetes mellitus; CI: Confidence intervals.

microvascular alterations may result in dysregulated neural activity [38]. These changes disrupt the balance of excitatory and inhibitory signaling, contributing to tinnitus perception [39]. Additionally, DM is a significant cause of peripheral neuropathy, which can impair auditory nerve function and result in abnormal firing patterns that the central auditory system interprets as tinnitus [8]. This highlights the role of DM-related nervous system damage in tinnitus, independent of cochlear issues [40]. Furthermore, DM can induce oxidative stress and inflammation, both of which are implicated in the pathogenesis of tinnitus [41, 42]. The glycation of proteins and lipids in DM leads to the formation of advanced glycation end products (AGEs), resulting in cellular dysfunction and inflammation in auditory tissues, further exacerbating tinnitus symptoms [43–45]. Given the complex interplay of these mechanisms, it is plausible that DM affects tinnitus through a combination of vascular, inflammatory, and metabolic pathways.

The sensitivity analyses conducted in this study were essential in confirming the robustness of the findings. Sequentially excluding individual studies did not lead to significant changes in the pooled effect estimates, demonstrating that the results were not disproportionately influenced by any single study. Furthermore, excluding the only study that specifically examined T2DM, as well as excluding lower-quality studies based on the NOS score, produced results consistent with the overall analysis. These findings suggest that the observed association between DM and tinnitus is neither restricted to a specific type of diabetes nor significantly affected by study quality. The moderate heterogeneity observed ($I^2 = 51\%$) was effectively addressed using a random-effects model, which accounts for variability among studies. Subgroup analyses were also performed to identify potential sources of heterogeneity. However, no significant differences were found based on factors, such as geographical region, mean age, sex distribution, tinnitus diagnostic methods, or statistical models employed. This consistency across subgroups suggests that the association between DM and tinnitus may be generalizable to diverse populations

and clinical settings. While this meta-analysis has several strengths, certain limitations should be acknowledged. First, the observational nature of the included studies limits the ability to infer causality between DM and tinnitus. Although the analysis provides evidence of an association, further prospective longitudinal studies are necessary to determine the temporal relationship and investigate whether DM directly contributes to tinnitus or whether other factors mediate this relationship. Second, there was variation in how DM and tinnitus were diagnosed across studies, introducing the possibility of misclassification bias. For example, some studies relied on self-reported tinnitus, whereas others used clinical diagnoses or ICD codes, which may differ in accuracy. Similarly, the methods for diagnosing DM ranged from medical records to ICD codes, with potential inconsistencies in diagnostic criteria influencing the observed association. Lastly, while most studies adjusted for key confounders, such as age and sex, residual confounding from unmeasured factors—such as comorbid conditions, lifestyle factors, or medication use-may still affect the association between DM and tinnitus.

The strengths of this meta-analysis include a comprehensive search strategy spanning multiple databases, the use of an established quality assessment tool NOS, and a thorough examination of heterogeneity through sensitivity and subgroup analyses. The large sample size and inclusion of studies from diverse geographic regions enhance the generalizability of the findings. By incorporating studies with a minimum sample size of 100 participants and excluding populations with specific diseases (e.g., cardiovascular or neurological disorders), the analysis minimizes potential confounding factors and strengthens the reliability of its conclusions. Although the 100-participant cutoff is somewhat arbitrary, this criterion was implemented to mitigate the influence of small, underpowered studies, which can lead to unstable results or exaggerated effect sizes [46]. Smaller studies are more susceptible to confounding and random error, which can bias meta-analytic findings [30]. Prior research has emphasized the risks of including underpowered

Α					Odds Ratio	Odds Ratio
^	Study or Subgroup	log[Odds Ratio]	SE	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
	1.2.1 Asian countries					
	Hong 2016	0.55961579	0.1695785	6.8%	1.75 [1.26, 2.44]	
	Li 2018	0.99694864	0.45669817	1.3%	2.71 [1.11, 6.63]	· · · · · · · · · · · · · · · · · · ·
	Chang 2019	-0.02020271		4.7%	0.98 [0.64, 1.50]	
	Choi 2021	0.06765865	0.16668542	6.9%	1.07 [0.77, 1.48]	
	Kuang 2022	0.0861777	0.0700094	16.3%	1.09 [0.95, 1.25]	
	Lee 2024	0.01980263	0.06977999	16.4%	1.02 [0.89, 1.17]	+
	Subtotal (95% CI)			52.3%	1.17 [0.98, 1.39]	•
	Heterogeneity: Tau ² = (0.02; Chi ² = 12.89,	df = 5 (P = 0.0)	02); I ² = 61		
	Test for overall effect: 2		•	,,		
	1.2.2 Non-Asian coun	trios				
	Martines 2015		0.57141569	0.8%	1.72 [0.56, 5.27]	
	Staudt 2019		0.20042616	5.3%	1.45 [0.98, 2.15]	
	Qian 2020		0.29749246	2.7%	1.11 [0.62, 1.99]	
	Loiselle 2020		0.03598944	20.8%	1.06 [0.99, 1.14]	-
	Chamouton 2021	0.47623418	0.16673	6.9%	1.61 [1.16, 2.23]	
	Zeleznik 2023		0.11290022	11.2%	1.21 [0.97, 1.51]	
	Subtotal (95% CI)	0.10002000	0.11200022	47.7%	1.23 [1.04, 1.45]	•
	Heterogeneity: Tau ² = ().02: Chi² = 9.50. d	f = 5 (P = 0.09)			
	Test for overall effect: Z			,,		
	Total (95% CI)			100.0%	1.18 [1.06, 1.31]	
	Heterogeneity: Tau ² = 0			.02); I ² = 5	1%	0.2 0.5 1 2 5
	Test for overall effect: 2	•				0.2 0.0 1 2 0
	Test for subaroup differ	ences: Chi ² = 0.18	. df = 1 (P = 0	.67). I ² = 0 ⁶	%	
					Odds Ratio	Odds Ratio
В	Study or Subaroup	log[Odds Ratio]	SE	Weight	Odds Ratio IV. Random, 95% CI	Odds Ratio IV. Random, 95% Cl
В	Study or Subgroup 1.3.1 Mean age < 55 v	•• •	SE	Weight	Odds Ratio IV, Random, 95% CI	Odds Ratio IV, Random, 95% CI
B	1.3.1 Mean age < 55 y	ears		-	IV, Random, 95% CI	
B	1.3.1 Mean age < 55 ye Hong 2016	ears 0.55961579	0.1695785	6.8%	IV, Random, 95% Cl 1.75 [1.26, 2.44]	
B	1.3.1 Mean age < 55 y Hong 2016 Staudt 2019	ears 0.55961579 0.37156356	0.1695785 0.20042616	6.8% 5.3%	IV. Random, 95% Cl 1.75 [1.26, 2.44] 1.45 [0.98, 2.15]	
B	1.3.1 Mean age < 55 yr Hong 2016 Staudt 2019 Qian 2020	ears 0.55961579 0.37156356 0.10436002	0.1695785 0.20042616 0.29749246	6.8% 5.3% 2.7%	IV. Random, 95% Cl 1.75 [1.26, 2.44] 1.45 [0.98, 2.15] 1.11 [0.62, 1.99]	
B	1.3.1 Mean age < 55 y Hong 2016 Staudt 2019 Qian 2020 Loiselle 2020	ears 0.55961579 0.37156356 0.10436002 0.05826891	0.1695785 0.20042616 0.29749246 0.03598944	6.8% 5.3% 2.7% 20.8%	IV. Random, 95% Cl 1.75 [1.26, 2.44] 1.45 [0.98, 2.15] 1.11 [0.62, 1.99] 1.06 [0.99, 1.14]	
Β.	1.3.1 Mean age < 55 yr Hong 2016 Staudt 2019 Qian 2020	ears 0.55961579 0.37156356 0.10436002 0.05826891 0.06765865	0.1695785 0.20042616 0.29749246 0.03598944 0.16668542	6.8% 5.3% 2.7% 20.8% 6.9%	IV. Random, 95% Cl 1.75 [1.26, 2.44] 1.45 [0.98, 2.15] 1.11 [0.62, 1.99] 1.06 [0.99, 1.14] 1.07 [0.77, 1.48]	
B	1.3.1 Mean age < 55 y Hong 2016 Staudt 2019 Qian 2020 Loiselle 2020 Choi 2021	ears 0.55961579 0.37156356 0.10436002 0.05826891 0.06765865	0.1695785 0.20042616 0.29749246 0.03598944	6.8% 5.3% 2.7% 20.8%	IV. Random, 95% Cl 1.75 [1.26, 2.44] 1.45 [0.98, 2.15] 1.11 [0.62, 1.99] 1.06 [0.99, 1.14] 1.07 [0.77, 1.48] 1.21 [0.97, 1.51]	
B	1.3.1 Mean age < 55 yr Hong 2016 Staudt 2019 Qian 2020 Loiselle 2020 Choi 2021 Zeleznik 2023 Subtotal (95% CI)	ears 0.55961579 0.37156356 0.10436002 0.05826891 0.06765865 0.19062036	0.1695785 0.20042616 0.29749246 0.03598944 0.16668542 0.11290022	6.8% 5.3% 2.7% 20.8% 6.9% 11.2% 53.7%	IV. Random, 95% Cl 1.75 [1.26, 2.44] 1.45 [0.98, 2.15] 1.11 [0.62, 1.99] 1.06 [0.99, 1.14] 1.07 [0.77, 1.48] 1.21 [0.97, 1.51] 1.22 [1.04, 1.43]	
Β.	1.3.1 Mean age < 55 y Hong 2016 Staudt 2019 Qian 2020 Loiselle 2020 Choi 2021 Zeleznik 2023	ears 0.55961579 0.37156356 0.10436002 0.05826891 0.06765865 0.19062036 0.02; Chi ² = 11.20,	0.1695785 0.20042616 0.29749246 0.03598944 0.16668542 0.11290022	6.8% 5.3% 2.7% 20.8% 6.9% 11.2% 53.7%	IV. Random, 95% Cl 1.75 [1.26, 2.44] 1.45 [0.98, 2.15] 1.11 [0.62, 1.99] 1.06 [0.99, 1.14] 1.07 [0.77, 1.48] 1.21 [0.97, 1.51] 1.22 [1.04, 1.43]	
Β.	1.3.1 Mean age < 55 yr Hong 2016 Staudt 2019 Qian 2020 Loiselle 2020 Choi 2021 Zeleznik 2023 Subtotal (95% CI) Heterogeneity: Tau ² = 0 Test for overall effect: 2	ears 0.55961579 0.37156356 0.10436002 0.05826891 0.06765865 0.19062036 0.02; Chi ² = 11.20, Z = 2.40 (P = 0.02)	0.1695785 0.20042616 0.29749246 0.03598944 0.16668542 0.11290022	6.8% 5.3% 2.7% 20.8% 6.9% 11.2% 53.7%	IV. Random, 95% Cl 1.75 [1.26, 2.44] 1.45 [0.98, 2.15] 1.11 [0.62, 1.99] 1.06 [0.99, 1.14] 1.07 [0.77, 1.48] 1.21 [0.97, 1.51] 1.22 [1.04, 1.43]	
B	1.3.1 Mean age < 55 yr Hong 2016 Staudt 2019 Qian 2020 Loiselle 2020 Choi 2021 Zeleznik 2023 Subtotal (95% Cl) Heterogeneity: Tau ² = 0 Test for overall effect: 2 1.3.2 Mean age \geq 55 yr	ears 0.55961579 0.37156356 0.10436002 0.05826891 0.06765865 0.19062036 0.02; Chi ² = 11.20, Z = 2.40 (P = 0.02) years	0.1695785 0.20042616 0.29749246 0.03598944 0.16668542 0.11290022 df = 5 (P = 0.0	6.8% 5.3% 2.7% 20.8% 6.9% 11.2% 53.7% 05); l ² = 55 ⁴	IV, Random, 95% CI 1.75 [1.26, 2.44] 1.45 [0.98, 2.15] 1.11 [0.62, 1.99] 1.06 [0.99, 1.14] 1.07 [0.77, 1.48] 1.21 [0.97, 1.51] 1.22 [1.04, 1.43] %	
B	1.3.1 Mean age < 55 yr Hong 2016 Staudt 2019 Qian 2020 Loiselle 2020 Choi 2021 Zeleznik 2023 Subtotal (95% Cl) Heterogeneity: Tau ² = 0 Test for overall effect: 2 1.3.2 Mean age \ge 55 yr Martines 2015	ears 0.55961579 0.37156356 0.10436002 0.05826891 0.06765865 0.19062036 0.02; Chi ² = 11.20, Z = 2.40 (P = 0.02) years 0.54232429	0.1695785 0.20042616 0.29749246 0.03598944 0.16668542 0.11290022 df = 5 (P = 0.0 0.57141569	6.8% 5.3% 2.7% 20.8% 6.9% 11.2% 53.7% 05); l ² = 55'	IV. Random, 95% CI 1.75 [1.26, 2.44] 1.45 [0.98, 2.15] 1.11 [0.62, 1.99] 1.06 [0.99, 1.14] 1.07 [0.77, 1.48] 1.21 [0.97, 1.51] 1.22 [1.04, 1.43] % 1.72 [0.56, 5.27]	
B	1.3.1 Mean age < 55 yr Hong 2016 Staudt 2019 Qian 2020 Loiselle 2020 Choi 2021 Zeleznik 2023 Subtotal (95% Cl) Heterogeneity: Tau ² = 0 Test for overall effect: 2 1.3.2 Mean age \geq 55 yr Martines 2015 Li 2018	ears 0.55961579 0.37156356 0.10436002 0.05826891 0.06765865 0.19062036 0.02; Chi ² = 11.20, Z = 2.40 (P = 0.02) years 0.54232429 0.99694864	0.1695785 0.20042616 0.29749246 0.03598944 0.16668542 0.11290022 df = 5 (P = 0.0 0.57141569 0.45669817	6.8% 5.3% 2.7% 20.8% 6.9% 11.2% 53.7% 05); l ² = 55' 0.8% 1.3%	IV. Random, 95% CI 1.75 [1.26, 2.44] 1.45 [0.98, 2.15] 1.11 [0.62, 1.99] 1.06 [0.99, 1.14] 1.07 [0.77, 1.48] 1.21 [0.97, 1.51] 1.22 [1.04, 1.43] % 1.72 [0.56, 5.27] 2.71 [1.11, 6.63]	
B	1.3.1 Mean age < 55 yr Hong 2016 Staudt 2019 Qian 2020 Loiselle 2020 Choi 2021 Zeleznik 2023 Subtotal (95% Cl) Heterogeneity: Tau ² = 0 Test for overall effect: \overline{z} 1.3.2 Mean age \geq 55 yr Martines 2015 Li 2018 Chang 2019	ears 0.55961579 0.37156356 0.10436002 0.05826891 0.06765865 0.19062036 0.02; Chi ² = 11.20, Z = 2.40 (P = 0.02) years 0.54232429 0.99694864 -0.02020271	0.1695785 0.20042616 0.29749246 0.03598944 0.16668542 0.11290022 df = 5 (P = 0.0 0.57141569 0.45669817 0.21728373	6.8% 5.3% 2.7% 20.8% 6.9% 11.2% 53.7% 05); l ² = 55' 0.8% 1.3% 4.7%	IV. Random, 95% Cl 1.75 [1.26, 2.44] 1.45 [0.98, 2.15] 1.11 [0.62, 1.99] 1.06 [0.99, 1.14] 1.07 [0.77, 1.48] 1.21 [0.97, 1.51] 1.22 [1.04, 1.43] % 1.72 [0.56, 5.27] 2.71 [1.11, 6.63] 0.98 [0.64, 1.50]	
Β.	1.3.1 Mean age < 55 yr Hong 2016 Staudt 2019 Qian 2020 Loiselle 2020 Choi 2021 Zeleznik 2023 Subtotal (95% CI) Heterogeneity: Tau ² = 0 Test for overall effect: \overline{z} 1.3.2 Mean age \geq 55 yr Martines 2015 Li 2018 Chang 2019 Chamouton 2021	ears 0.55961579 0.37156356 0.10436002 0.05826891 0.06765865 0.19062036 0.02; Chi ² = 11.20, Z = 2.40 (P = 0.02) years 0.54232429 0.99694864 -0.02020271 0.47623418	0.1695785 0.20042616 0.29749246 0.03598944 0.16668542 0.11290022 df = 5 (P = 0.0 0.57141569 0.45669817 0.21728373 0.16673	6.8% 5.3% 2.7% 20.8% 6.9% 11.2% 53.7% 05); l ² = 55' 0.8% 1.3% 4.7% 6.9%	1.75 [1.26, 2.44] 1.45 [0.98, 2.15] 1.11 [0.62, 1.99] 1.06 [0.99, 1.14] 1.07 [0.77, 1.48] 1.21 [0.97, 1.51] 1.22 [1.04, 1.43] % 1.72 [0.56, 5.27] 2.71 [1.11, 6.63] 0.98 [0.64, 1.50] 1.61 [1.16, 2.23]	
Β.	1.3.1 Mean age < 55 yr Hong 2016 Staudt 2019 Qian 2020 Loiselle 2020 Choi 2021 Zeleznik 2023 Subtotal (95% Cl) Heterogeneity: Tau ² = 0 Test for overall effect: \overline{z} 1.3.2 Mean age \geq 55 yr Martines 2015 Li 2018 Chang 2019	ears 0.55961579 0.37156356 0.10436002 0.05826891 0.06765865 0.19062036 0.02; Chi ² = 11.20, Z = 2.40 (P = 0.02) years 0.54232429 0.99694864 -0.02020271 0.47623418 0.0861777	0.1695785 0.20042616 0.29749246 0.03598944 0.16668542 0.11290022 df = 5 (P = 0.0 0.57141569 0.45669817 0.21728373	6.8% 5.3% 2.7% 20.8% 6.9% 11.2% 53.7% 05); l ² = 55' 0.8% 1.3% 4.7%	IV. Random, 95% Cl 1.75 [1.26, 2.44] 1.45 [0.98, 2.15] 1.11 [0.62, 1.99] 1.06 [0.99, 1.14] 1.07 [0.77, 1.48] 1.21 [0.97, 1.51] 1.22 [1.04, 1.43] % 1.72 [0.56, 5.27] 2.71 [1.11, 6.63] 0.98 [0.64, 1.50]	
Β.	1.3.1 Mean age < 55 yr Hong 2016 Staudt 2019 Qian 2020 Loiselle 2020 Choi 2021 Zeleznik 2023 Subtotal (95% CI) Heterogeneity: Tau ² = 0 Test for overall effect: \overline{z} 1.3.2 Mean age \geq 55 yr Martines 2015 Li 2018 Chang 2019 Chamouton 2021 Kuang 2022	ears 0.55961579 0.37156356 0.10436002 0.05826891 0.06765865 0.19062036 0.02; Chi ² = 11.20, Z = 2.40 (P = 0.02) years 0.54232429 0.99694864 -0.02020271 0.47623418 0.0861777	0.1695785 0.20042616 0.29749246 0.03598944 0.16668542 0.11290022 df = 5 (P = 0.0 0.57141569 0.45669817 0.21728373 0.16673 0.0700094	6.8% 5.3% 2.7% 20.8% 6.9% 11.2% 53.7% 05); l ² = 55' 0.8% 1.3% 4.7% 6.9% 16.3%	1.75 [1.26, 2.44] 1.45 [0.98, 2.15] 1.11 [0.62, 1.99] 1.06 [0.99, 1.14] 1.07 [0.77, 1.48] 1.21 [0.97, 1.51] 1.22 [1.04, 1.43] % 1.72 [0.56, 5.27] 2.71 [1.11, 6.63] 0.98 [0.64, 1.50] 1.61 [1.16, 2.23] 1.09 [0.95, 1.25]	
Β.	1.3.1 Mean age < 55 yr Hong 2016 Staudt 2019 Qian 2020 Loiselle 2020 Choi 2021 Zeleznik 2023 Subtotal (95% Cl) Heterogeneity: Tau ² = 0 Test for overall effect: \overline{z} 1.3.2 Mean age \geq 55 yr Martines 2015 Li 2018 Chang 2019 Chamouton 2021 Kuang 2022 Lee 2024 Subtotal (95% Cl) Heterogeneity: Tau ² = 0	ears 0.55961579 0.37156356 0.10436002 0.05826891 0.06765865 0.19062036 0.02; Chi ² = 11.20, Z = 2.40 (P = 0.02) years 0.54232429 0.99694864 -0.02020271 0.47623418 0.0861777 0.01980263 0.02; Chi ² = 11.20,	0.1695785 0.20042616 0.29749246 0.03598944 0.16668542 0.11290022 df = 5 (P = 0.0 0.57141569 0.45669817 0.21728373 0.16673 0.0700094 0.06977999 df = 5 (P = 0.0	6.8% 5.3% 2.7% 20.8% 6.9% 11.2% 53.7% 05); l ² = 55' 0.8% 1.3% 4.7% 6.9% 16.3% 16.4% 46.3 %	1.75 [1.26, 2.44] 1.45 [0.98, 2.15] 1.11 [0.62, 1.99] 1.06 [0.99, 1.14] 1.07 [0.77, 1.48] 1.21 [0.97, 1.51] 1.22 [1.04, 1.43] % 1.72 [0.56, 5.27] 2.71 [1.11, 6.63] 0.98 [0.64, 1.50] 1.61 [1.16, 2.23] 1.09 [0.95, 1.25] 1.02 [0.89, 1.17] 1.18 [0.98, 1.41]	
Β.	1.3.1 Mean age < 55 yr Hong 2016 Staudt 2019 Qian 2020 Loiselle 2020 Choi 2021 Zeleznik 2023 Subtotal (95% Cl) Heterogeneity: Tau ² = 0 Test for overall effect: \overline{z} 1.3.2 Mean age \geq 55 yr Martines 2015 Li 2018 Chang 2019 Chamouton 2021 Kuang 2022 Lee 2024 Subtotal (95% Cl)	ears 0.55961579 0.37156356 0.10436002 0.05826891 0.06765865 0.19062036 0.02; Chi ² = 11.20, Z = 2.40 (P = 0.02) years 0.54232429 0.99694864 -0.02020271 0.47623418 0.0861777 0.01980263 0.02; Chi ² = 11.20,	0.1695785 0.20042616 0.29749246 0.03598944 0.16668542 0.11290022 df = 5 (P = 0.0 0.57141569 0.45669817 0.21728373 0.16673 0.0700094 0.06977999 df = 5 (P = 0.0	6.8% 5.3% 2.7% 20.8% 6.9% 11.2% 53.7% 05); l ² = 55' 0.8% 1.3% 4.7% 6.9% 16.3% 16.4% 46.3 %	1.75 [1.26, 2.44] 1.45 [0.98, 2.15] 1.11 [0.62, 1.99] 1.06 [0.99, 1.14] 1.07 [0.77, 1.48] 1.21 [0.97, 1.51] 1.22 [1.04, 1.43] % 1.72 [0.56, 5.27] 2.71 [1.11, 6.63] 0.98 [0.64, 1.50] 1.61 [1.16, 2.23] 1.09 [0.95, 1.25] 1.02 [0.89, 1.17] 1.18 [0.98, 1.41]	
Β.	1.3.1 Mean age < 55 yr Hong 2016 Staudt 2019 Qian 2020 Loiselle 2020 Choi 2021 Zeleznik 2023 Subtotal (95% Cl) Heterogeneity: Tau ² = 0 Test for overall effect: \overline{z} 1.3.2 Mean age \geq 55 yr Martines 2015 Li 2018 Chang 2019 Chamouton 2021 Kuang 2022 Lee 2024 Subtotal (95% Cl) Heterogeneity: Tau ² = 0	ears 0.55961579 0.37156356 0.10436002 0.05826891 0.06765865 0.19062036 0.02; Chi ² = 11.20, Z = 2.40 (P = 0.02) years 0.54232429 0.99694864 -0.02020271 0.47623418 0.0861777 0.01980263 0.02; Chi ² = 11.20,	0.1695785 0.20042616 0.29749246 0.03598944 0.16668542 0.11290022 df = 5 (P = 0.0 0.57141569 0.45669817 0.21728373 0.16673 0.0700094 0.06977999 df = 5 (P = 0.0	6.8% 5.3% 2.7% 20.8% 6.9% 11.2% 53.7% 05); l ² = 55' 0.8% 1.3% 4.7% 6.9% 16.3% 16.4% 46.3 %	1.75 [1.26, 2.44] 1.45 [0.98, 2.15] 1.11 [0.62, 1.99] 1.06 [0.99, 1.14] 1.07 [0.77, 1.48] 1.21 [0.97, 1.51] 1.22 [1.04, 1.43] % 1.72 [0.56, 5.27] 2.71 [1.11, 6.63] 0.98 [0.64, 1.50] 1.61 [1.16, 2.23] 1.09 [0.95, 1.25] 1.02 [0.89, 1.17] 1.18 [0.98, 1.41]	
Β.	1.3.1 Mean age < 55 yr Hong 2016 Staudt 2019 Qian 2020 Loiselle 2020 Choi 2021 Zeleznik 2023 Subtotal (95% CI) Heterogeneity: Tau ² = 0 Test for overall effect: \overline{z} 1.3.2 Mean age \geq 55 yr Martines 2015 Li 2018 Chang 2019 Chamouton 2021 Kuang 2022 Lee 2024 Subtotal (95% CI) Heterogeneity: Tau ² = 0 Test for overall effect: \overline{z}	ears 0.55961579 0.37156356 0.10436002 0.05826891 0.06765865 0.19062036 0.02; Chi ² = 11.20, Z = 2.40 (P = 0.02) years 0.54232429 0.99694864 -0.02020271 0.47623418 0.0861777 0.01980263 0.02; Chi ² = 11.20, Z = 1.78 (P = 0.08)	0.1695785 0.20042616 0.29749246 0.03598944 0.16668542 0.11290022 df = 5 (P = 0.0 0.57141569 0.45669817 0.21728373 0.16673 0.0700094 0.06977999 df = 5 (P = 0.0	6.8% 5.3% 2.7% 20.8% 6.9% 11.2% 53.7% 05); l ² = 55' 0.8% 1.3% 4.7% 6.9% 16.3% 16.4% 46.3% 05); l ² = 55' 100.0%	IV. Random, 95% CI 1.75 [1.26, 2.44] 1.45 [0.98, 2.15] 1.11 [0.62, 1.99] 1.06 [0.99, 1.14] 1.07 [0.77, 1.48] 1.21 [0.97, 1.51] 1.22 [1.04, 1.43] % 1.72 [0.56, 5.27] 2.71 [1.11, 6.63] 0.98 [0.64, 1.50] 1.61 [1.16, 2.23] 1.09 [0.95, 1.25] 1.02 [0.89, 1.17] 1.18 [0.98, 1.41]	IV, Random, 95% Cl
Β.	1.3.1 Mean age < 55 yr Hong 2016 Staudt 2019 Qian 2020 Loiselle 2020 Choi 2021 Zeleznik 2023 Subtotal (95% CI) Heterogeneity: Tau ² = 0 Test for overall effect: 2 1.3.2 Mean age \ge 55 yr Martines 2015 Li 2018 Chang 2019 Chamouton 2021 Kuang 2022 Lee 2024 Subtotal (95% CI) Heterogeneity: Tau ² = 0 Test for overall effect: 2	ears 0.55961579 0.37156356 0.10436002 0.05826891 0.06765865 0.19062036 0.02; Chi ² = 11.20, Z = 2.40 (P = 0.02) years 0.54232429 0.99694864 -0.02020271 0.47623418 0.0861777 0.01980263 0.02; Chi ² = 11.20, Z = 1.78 (P = 0.08) 0.01; Chi ² = 22.40, Z = 3.14 (P = 0.002)	0.1695785 0.20042616 0.29749246 0.03598944 0.16668542 0.11290022 df = 5 (P = 0.0 0.57141569 0.45669817 0.21728373 0.16673 0.0700094 0.06977999 df = 5 (P = 0.0 df = 11 (P = 0	6.8% 5.3% 2.7% 20.8% 6.9% 11.2% 53.7% 05); l ² = 55' 0.8% 1.3% 4.7% 6.9% 16.3% 16.4% 46.3% 05); l ² = 55' 100.0% .02); l ² = 5	IV. Random, 95% CI 1.75 [1.26, 2.44] 1.45 [0.98, 2.15] 1.11 [0.62, 1.99] 1.06 [0.99, 1.14] 1.07 [0.77, 1.48] 1.21 [0.97, 1.51] 1.22 [1.04, 1.43] % 1.72 [0.56, 5.27] 2.71 [1.11, 6.63] 0.98 [0.64, 1.50] 1.61 [1.16, 2.23] 1.09 [0.95, 1.25] 1.02 [0.89, 1.17] 1.18 [0.98, 1.41] %	

Figure 3. Forest plots for the subgroup analyses of the association between DM and tinnitus. (A) The subgroup analysis according to study country and (B) The subgroup analysis according to the mean age of the participants. DM: Diabetes mellitus; CI: Confidence intervals.

				Odds Ratio	Odds Ratio
Study or Subgroup	log[Odds Ratio]	SE	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.4.1 Men < 48%					
Hong 2016	0.55961579	0.1695785	6.8%	1.75 [1.26, 2.44]	
Staudt 2019	0.37156356	0.20042616	5.3%	1.45 [0.98, 2.15]	
Loiselle 2020	0.05826891		20.8%	1.06 [0.99, 1.14]	-
Chamouton 2021	0.47623418	0.16673	6.9%	1.61 [1.16, 2.23]	
Kuang 2022	0.0861777	0.0700094	16.3%	1.09 [0.95, 1.25]	
Zeleznik 2023	0.19062036	0.11290022	11.2%	1.21 [0.97, 1.51]	-
Subtotal (95% CI)			67.2%	1.25 [1.08, 1.45]	•
Heterogeneity: Tau ² =	0.02; Chi² = 16.24,	df = 5 (P = 0.0	006); I² = 6	9%	
Test for overall effect:	Z = 3.01 (P = 0.003)			
1.4.2 Men ≥ 48%					
Martines 2015	0.54232429	0.57141569	0.8%	1.72 [0.56, 5.27]	
Li 2018	0.99694864		1.3%	2.71 [1.11, 6.63]	
Chang 2019	-0.02020271	0.21728373	4.7%	0.98 [0.64, 1.50]	
Qian 2020	0.10436002		2.7%	1.11 [0.62, 1.99]	
Choi 2021	0.06765865	0.16668542	6.9%	1.07 [0.77, 1.48]	-+
Lee 2024	0.01980263	0.06977999	16.4%	1.02 [0.89, 1.17]	<u>+</u>
Subtotal (95% CI)			32.8%	1.06 [0.92, 1.22]	•
Heterogeneity: Tau ² =	0.00; Chi ² = 5.38, d	f = 5 (P = 0.3	7); l² = 7%		
Test for overall effect:	Z = 0.84 (P = 0.40)				
			100.0%	1.18 [1.06, 1.31]	◆
Total (95% CI)			001.12 - 5	10/	
	0.01; Chi ² = 22.40,	df = 11 (P = 0)	1.0Z); I^ = 5	170	
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect:			0.02); 1- = 5	01%	0.2 0.5 1 2 5
Heterogeneity: Tau ² =	Z = 3.14 (P = 0.002)			0.2 0.5 1 2 5
Heterogeneity: Tau ² = Test for overall effect:	Z = 3.14 (P = 0.002)		0.8%	
Heterogeneity: Tau ² = Test for overall effect: Test for suboroup diffe	Z = 3.14 (P = 0.002 erences: Chi ² = 2.55) . df = 1 (P = 0	0.11). I² = 6	0.8% Odds Ratio	Odds Ratio
Heterogeneity: Tau ² = Test for overall effect: Test for subaroup diffe <u>Study or Subgroup</u>	Z = 3.14 (P = 0.002 erences: Chi ² = 2.55 log[Odds Ratio]) . df = 1 (P = 0	0.11). I² = 6	0.8%	
Heterogeneity: Tau ² = Test for overall effect: Test for subaroup diffe <u>Study or Subgroup</u> 1.5.1 Clinical diagnos	Z = 3.14 (P = 0.002 erences: Chi ² = 2.55 <u>log[Odds Ratio]</u> sis) . df = 1 (P = 0 SE	0.11). I ² = 6 <u>Weight</u>	0.8% Odds Ratio IV, Random, 95% Cl	Odds Ratio
Heterogeneity: Tau ² = Test for overall effect: Test for subaroup diffe <u>Study or Subgroup</u> 1.5.1 Clinical diagnos Martines 2015	Z = 3.14 (P = 0.002 prences: Chi ² = 2.55 log[Odds Ratio] sis 0.54232429) . df = 1 (P = 0 <u>SE</u> 0.57141569	0.11). I ² = 6 <u>Weight</u> 0.8%	0.8% Odds Ratio IV. Random. 95% CI 1.72 [0.56, 5.27]	Odds Ratio
Heterogeneity: Tau ² = Test for overall effect: Test for suboroup diffe <u>Study or Subgroup</u> 1.5.1 Clinical diagnos Martines 2015 Hong 2016	Z = 3.14 (P = 0.002 prences: Chi ² = 2.55 <u>log[Odds Ratio]</u> sis 0.54232429 0.55961579) . df = 1 (P = 0 <u>SE</u> 0.57141569 0.1695785	0.11). I ² = 6 <u>Weight</u> 0.8% 6.8%	0.8% Odds Ratio <u>IV. Random, 95% CI</u> 1.72 [0.56, 5.27] 1.75 [1.26, 2.44]	Odds Ratio
Heterogeneity: Tau ² = Test for overall effect: Test for suboroup diffe <u>Study or Subgroup</u> 1.5.1 Clinical diagnos Martines 2015 Hong 2016 Li 2018	Z = 3.14 (P = 0.002 prences: Chi ² = 2.55 log[Odds Ratio] sis 0.54232429 0.55961579 0.99694864) . df = 1 (P = 0 <u>SE</u> 0.57141569 0.1695785 0.45669817	0.11). I ² = 6 Weight 0.8% 6.8% 1.3%	0.8% Odds Ratio <u>IV, Random, 95% CI</u> 1.72 [0.56, 5.27] 1.75 [1.26, 2.44] 2.71 [1.11, 6.63]	Odds Ratio
Heterogeneity: Tau ² = Test for overall effect: Test for subaroup diffe <u>Study or Subgroup</u> 1.5.1 Clinical diagnos Martines 2015 Hong 2016 Li 2018 Chang 2019	Z = 3.14 (P = 0.002 prences: Chi ² = 2.55 log[Odds Ratio] sis 0.54232429 0.55961579 0.99694864 -0.02020271) . df = 1 (P = 0 SE 0.57141569 0.1695785 0.45669817 0.21728373	0.11). I ² = 6 Weight 0.8% 6.8% 1.3% 4.7%	0.8% Odds Ratio <u>IV, Random, 95% CI</u> 1.72 [0.56, 5.27] 1.75 [1.26, 2.44] 2.71 [1.11, 6.63] 0.98 [0.64, 1.50]	Odds Ratio
Heterogeneity: Tau ² = Test for overall effect: Test for subaroup diffe <u>Study or Subgroup</u> 1.5.1 Clinical diagnos Martines 2015 Hong 2016 Li 2018 Chang 2019 Qian 2020	Z = 3.14 (P = 0.002 prences: Chi ² = 2.55 log[Odds Ratio] sis 0.54232429 0.55961579 0.99694864) . df = 1 (P = 0 SE 0.57141569 0.1695785 0.45669817 0.21728373	0.11). I ² = 6 Weight 0.8% 6.8% 1.3% 4.7% 2.7%	0.8% Odds Ratio IV, Random, 95% CI 1.72 [0.56, 5.27] 1.75 [1.26, 2.44] 2.71 [1.11, 6.63] 0.98 [0.64, 1.50] 1.11 [0.62, 1.99]	Odds Ratio
Heterogeneity: Tau ² = Test for overall effect: Test for subaroup diffe Study or Subgroup 1.5.1 Clinical diagnos Martines 2015 Hong 2016 Li 2018 Chang 2019 Qian 2020 Subtotal (95% CI)	Z = 3.14 (P = 0.002 prences: Chi ² = 2.55 log[Odds Ratio] sis 0.54232429 0.55961579 0.99694864 -0.02020271 0.10436002) . df = 1 (P = 0 SE 0.57141569 0.1695785 0.45669817 0.21728373 0.29749246	0.11). I ² = 6 Weight 0.8% 6.8% 1.3% 4.7% 2.7% 16.2%	O.8% Odds Ratio IV. Random. 95% CI 1.72 [0.56, 5.27] 1.75 [1.26, 2.44] 2.71 [1.11, 6.63] 0.98 [0.64, 1.50] 1.11 [0.62, 1.99] 1.43 [1.01, 2.01]	Odds Ratio
Heterogeneity: Tau ² = Test for overall effect: Test for subaroup diffe <u>Study or Subgroup</u> 1.5.1 Clinical diagnos Martines 2015 Hong 2016 Li 2018 Chang 2019 Qian 2020	Z = 3.14 (P = 0.002 prences: Chi ² = 2.55 log[Odds Ratio] sis 0.54232429 0.55961579 0.99694864 -0.02020271 0.10436002 0.06; Chi ² = 7.23, d) . df = 1 (P = 0 SE 0.57141569 0.1695785 0.45669817 0.21728373 0.29749246	0.11). I ² = 6 Weight 0.8% 6.8% 1.3% 4.7% 2.7% 16.2%	O.8% Odds Ratio IV. Random. 95% CI 1.72 [0.56, 5.27] 1.75 [1.26, 2.44] 2.71 [1.11, 6.63] 0.98 [0.64, 1.50] 1.11 [0.62, 1.99] 1.43 [1.01, 2.01]	Odds Ratio
Heterogeneity: Tau ² = Test for overall effect: Test for subaroup diffe Study or Subgroup 1.5.1 Clinical diagnos Martines 2015 Hong 2016 Li 2018 Chang 2019 Qian 2020 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect:	Z = 3.14 (P = 0.002 prences: Chi ² = 2.55 log[Odds Ratio] sis 0.54232429 0.55961579 0.99694864 -0.02020271 0.10436002 0.06; Chi ² = 7.23 , d Z = 2.03 (P = 0.04)) . df = 1 (P = 0 SE 0.57141569 0.1695785 0.45669817 0.21728373 0.29749246	0.11). I ² = 6 Weight 0.8% 6.8% 1.3% 4.7% 2.7% 16.2%	O.8% Odds Ratio IV. Random. 95% CI 1.72 [0.56, 5.27] 1.75 [1.26, 2.44] 2.71 [1.11, 6.63] 0.98 [0.64, 1.50] 1.11 [0.62, 1.99] 1.43 [1.01, 2.01]	Odds Ratio
Heterogeneity: Tau ² = Test for overall effect: Test for suboroup differ Study or Subgroup 1.5.1 Clinical diagnos Martines 2015 Hong 2016 Li 2018 Chang 2019 Qian 2020 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect: 1.5.2 Self-report or IC	Z = 3.14 (P = 0.002 rences: Chi ² = 2.55 log[Odds Ratio] sis 0.54232429 0.55961579 0.99694864 -0.02020271 0.10436002 0.06; Chi ² = 7.23, d Z = 2.03 (P = 0.04) C odes) . df = 1 (P = 0 SE 0.57141569 0.1695785 0.45669817 0.21728373 0.29749246 f = 4 (P = 0.12	0.11). I ² = 6 Weight 0.8% 6.8% 1.3% 4.7% 2.7% 16.2% 2); I ² = 459	O.8% Odds Ratio IV. Random. 95% CI 1.72 [0.56, 5.27] 1.75 [1.26, 2.44] 2.71 [1.11, 6.63] 0.98 [0.64, 1.50] 1.11 [0.62, 1.99] 1.43 [1.01, 2.01]	Odds Ratio
Heterogeneity: Tau ² = Test for overall effect: Test for suboroup differ Study or Subgroup 1.5.1 Clinical diagnos Martines 2015 Hong 2016 Li 2018 Chang 2019 Qian 2020 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect: 1.5.2 Self-report or IC Staudt 2019	Z = 3.14 (P = 0.002 rences: Chi ² = 2.55 log[Odds Ratio] sis 0.54232429 0.55961579 0.99694864 -0.02020271 0.10436002 0.06; Chi ² = 7.23, d Z = 2.03 (P = 0.04) CD codes 0.37156356) . df = 1 (P = 0 SE 0.57141569 0.1695785 0.45669817 0.21728373 0.29749246 f = 4 (P = 0.12 0.20042616	0.11). I ² = 6 Weight 0.8% 6.8% 1.3% 4.7% 2.7% 16.2% 2); I ² = 45% 5.3%	O.8% Odds Ratio IV. Random. 95% Cl 1.72 [0.56, 5.27] 1.75 [1.26, 2.44] 2.71 [1.11, 6.63] 0.98 [0.64, 1.50] 1.11 [0.62, 1.99] 1.43 [1.01, 2.01] % 1.45 [0.98, 2.15]	Odds Ratio
Heterogeneity: Tau ² = Test for overall effect: Test for suboroup differ Study or Subgroup 1.5.1 Clinical diagnos Martines 2015 Hong 2016 Li 2018 Chang 2019 Qian 2020 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect: 1.5.2 Self-report or IC	Z = 3.14 (P = 0.002 rences: Chi ² = 2.55 log[Odds Ratio] sis 0.54232429 0.55961579 0.99694864 -0.02020271 0.10436002 0.06; Chi ² = 7.23, d Z = 2.03 (P = 0.04) CD codes 0.37156356) . df = 1 (P = 0 SE 0.57141569 0.1695785 0.45669817 0.21728373 0.29749246 f = 4 (P = 0.12 0.20042616	0.11). I ² = 6 Weight 0.8% 6.8% 1.3% 4.7% 2.7% 16.2% 2); I ² = 45% 5.3% 20.8%	O.8% Odds Ratio IV. Random. 95% Cl 1.72 [0.56, 5.27] 1.75 [1.26, 2.44] 2.71 [1.11, 6.63] 0.98 [0.64, 1.50] 1.11 [0.62, 1.99] 1.43 [1.01, 2.01] 6 1.45 [0.98, 2.15] 1.06 [0.99, 1.14]	Odds Ratio
Heterogeneity: Tau ² = Test for overall effect: Test for suboroup differ Study or Subgroup 1.5.1 Clinical diagnos Martines 2015 Hong 2016 Li 2018 Chang 2019 Qian 2020 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect: 1.5.2 Self-report or IC Staudt 2019 Loiselle 2020	Z = 3.14 (P = 0.002 rences: Chi ² = 2.55 log[Odds Ratio] sis 0.54232429 0.55961579 0.99694864 -0.02020271 0.10436002 0.06; Chi ² = 7.23, d Z = 2.03 (P = 0.04) CD codes 0.37156356 0.05826891 0.47623418) . df = 1 (P = 0 SE 0.57141569 0.1695785 0.45669817 0.21728373 0.29749246 f = 4 (P = 0.12 0.20042616 0.03598944 0.16673	0.11). I ² = 6 Weight 0.8% 6.8% 1.3% 4.7% 2.7% 16.2% 2); I ² = 45% 5.3% 20.8% 6.9%	O.8% Odds Ratio IV. Random. 95% Cl 1.72 [0.56, 5.27] 1.75 [1.26, 2.44] 2.71 [1.11, 6.63] 0.98 [0.64, 1.50] 1.11 [0.62, 1.99] 1.43 [1.01, 2.01] 6 1.45 [0.98, 2.15] 1.06 [0.99, 1.14] 1.61 [1.16, 2.23]	Odds Ratio
Heterogeneity: Tau ² = Test for overall effect: Test for subaroub differ Study or Subgroup 1.5.1 Clinical diagnos Martines 2015 Hong 2016 Li 2018 Chang 2019 Qian 2020 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect: 1.5.2 Self-report or IC Staudt 2019 Loiselle 2020 Chamouton 2021	Z = 3.14 (P = 0.002 rences: Chi ² = 2.55 log[Odds Ratio] sis 0.54232429 0.55961579 0.99694864 -0.02020271 0.10436002 0.06; Chi ² = 7.23, d Z = 2.03 (P = 0.04) CD codes 0.37156356 0.05826891) . df = 1 (P = 0 SE 0.57141569 0.1695785 0.45669817 0.21728373 0.29749246 f = 4 (P = 0.12 0.20042616 0.03598944 0.16673 0.16668542	0.11). I ² = 6 Weight 0.8% 6.8% 1.3% 4.7% 2.7% 16.2% 2); I ² = 45% 5.3% 20.8% 6.9% 6.9%	O.8% Odds Ratio IV. Random. 95% Cl 1.72 [0.56, 5.27] 1.75 [1.26, 2.44] 2.71 [1.11, 6.63] 0.98 [0.64, 1.50] 1.11 [0.62, 1.99] 1.43 [1.01, 2.01] 6 1.45 [0.98, 2.15] 1.06 [0.99, 1.14] 1.61 [1.16, 2.23] 1.07 [0.77, 1.48]	Odds Ratio
Heterogeneity: Tau ² = Test for overall effect: Test for subaroub differ Study or Subgroup 1.5.1 Clinical diagnos Martines 2015 Hong 2016 Li 2018 Chang 2019 Qian 2020 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect: 1.5.2 Self-report or IC Staudt 2019 Loiselle 2020 Chamouton 2021 Choi 2021	Z = 3.14 (P = 0.002 rences: Chi ² = 2.55 log[Odds Ratio] sis 0.54232429 0.55961579 0.99694864 -0.02020271 0.10436002 0.06; Chi ² = 7.23, d Z = 2.03 (P = 0.04) CD codes 0.37156356 0.05826891 0.47623418 0.06765865 0.0861777) . df = 1 (P = 0 SE 0.57141569 0.1695785 0.45669817 0.21728373 0.29749246 f = 4 (P = 0.12 0.20042616 0.03598944 0.16673 0.16668542 0.0700094	0.11). I ² = 6 Weight 0.8% 6.8% 1.3% 4.7% 2.7% 16.2% 2); I ² = 45% 5.3% 20.8% 6.9% 6.9% 16.3%	O.8% Odds Ratio IV. Random. 95% Cl 1.72 [0.56, 5.27] 1.75 [1.26, 2.44] 2.71 [1.11, 6.63] 0.98 [0.64, 1.50] 1.11 [0.62, 1.99] 1.43 [1.01, 2.01] 4 1.45 [0.98, 2.15] 1.06 [0.99, 1.14] 1.61 [1.16, 2.23] 1.07 [0.77, 1.48] 1.09 [0.95, 1.25]	Odds Ratio
Heterogeneity: Tau ² = Test for overall effect: Test for subaroup differ Study or Subgroup 1.5.1 Clinical diagnos Martines 2015 Hong 2016 Li 2018 Chang 2019 Qian 2020 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect: 1.5.2 Self-report or IC Staudt 2019 Loiselle 2020 Chamouton 2021 Choi 2021 Kuang 2022	Z = 3.14 (P = 0.002 rences: Chi ² = 2.55 log[Odds Ratio] sis 0.54232429 0.55961579 0.99694864 -0.02020271 0.10436002 0.06; Chi ² = 7.23, d Z = 2.03 (P = 0.04) CD codes 0.37156356 0.05826891 0.47623418 0.06765865) . df = 1 (P = 0 SE 0.57141569 0.1695785 0.45669817 0.21728373 0.29749246 f = 4 (P = 0.12 0.20042616 0.03598944 0.16673 0.16668542 0.0700094 0.11290022	0.11). I ² = 6 Weight 0.8% 6.8% 1.3% 4.7% 2.7% 16.2% 2); I ² = 45% 5.3% 20.8% 6.9% 6.9%	O.8% Odds Ratio IV. Random. 95% Cl 1.72 [0.56, 5.27] 1.75 [1.26, 2.44] 2.71 [1.11, 6.63] 0.98 [0.64, 1.50] 1.11 [0.62, 1.99] 1.43 [1.01, 2.01] 6 1.45 [0.98, 2.15] 1.06 [0.99, 1.14] 1.61 [1.16, 2.23] 1.07 [0.77, 1.48]	Odds Ratio
Heterogeneity: Tau ² = Test for overall effect: Test for subaroub differ Study or Subgroup 1.5.1 Clinical diagnos Martines 2015 Hong 2016 Li 2018 Chang 2019 Qian 2020 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect: 1.5.2 Self-report or IC Staudt 2019 Loiselle 2020 Chamouton 2021 Choi 2021 Kuang 2022 Zeleznik 2023	Z = 3.14 (P = 0.002 rences: Chi ² = 2.55 log[Odds Ratio] sis 0.54232429 0.55961579 0.99694864 -0.02020271 0.10436002 0.06; Chi ² = 7.23, d Z = 2.03 (P = 0.04) CD codes 0.37156356 0.05826891 0.47623418 0.06765865 0.0861777 0.19062036) . df = 1 (P = 0 SE 0.57141569 0.1695785 0.45669817 0.21728373 0.29749246 f = 4 (P = 0.12 0.20042616 0.03598944 0.16673 0.16668542 0.0700094 0.11290022	0.11). I ² = 6 Weight 0.8% 6.8% 1.3% 4.7% 2.7% 16.2% 2); I ² = 45% 5.3% 20.8% 6.9% 6.9% 16.3% 11.2%	O.8% Odds Ratio IV. Random. 95% Cl 1.72 [0.56, 5.27] 1.75 [1.26, 2.44] 2.71 [1.11, 6.63] 0.98 [0.64, 1.50] 1.11 [0.62, 1.99] 1.43 [1.01, 2.01] 4 1.45 [0.98, 2.15] 1.06 [0.99, 1.14] 1.61 [1.16, 2.23] 1.07 [0.77, 1.48] 1.09 [0.95, 1.25] 1.21 [0.97, 1.51]	Odds Ratio
Heterogeneity: Tau ² = Test for overall effect: Test for subaroub differ Study or Subgroup 1.5.1 Clinical diagnos Martines 2015 Hong 2016 Li 2018 Chang 2019 Qian 2020 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect: 1.5.2 Self-report or IC Staudt 2019 Loiselle 2020 Chamouton 2021 Choi 2021 Kuang 2022 Zeleznik 2023 Lee 2024	Z = 3.14 (P = 0.002 rences: Chi ² = 2.55 log[Odds Ratio] sis 0.54232429 0.55961579 0.99694864 -0.02020271 0.10436002 0.06; Chi ² = 7.23, d Z = 2.03 (P = 0.04) CD codes 0.37156356 0.05826891 0.47623418 0.06765865 0.0861777 0.19062036 0.01980263) . df = 1 (P = 0 <u>SE</u> 0.57141569 0.1695785 0.45669817 0.21728373 0.29749246 f = 4 (P = 0.12 0.20042616 0.03598944 0.16673 0.16668542 0.0700094 0.11290022 0.06977999	0.11). I ² = 6 Weight 0.8% 6.8% 1.3% 4.7% 2.7% 16.2% 2); I ² = 45% 5.3% 20.8% 6.9% 6.9% 16.3% 11.2% 16.4% 83.8%	Odds Ratio IV. Random. 95% Cl 1.72 [0.56, 5.27] 1.75 [1.26, 2.44] 2.71 [1.11, 6.63] 0.98 [0.64, 1.50] 1.11 [0.62, 1.99] 1.43 [1.01, 2.01] 4 1.45 [0.98, 2.15] 1.06 [0.99, 1.14] 1.61 [1.16, 2.23] 1.07 [0.77, 1.48] 1.09 [0.95, 1.25] 1.21 [0.97, 1.51] 1.02 [0.89, 1.17] 1.12 [1.02, 1.21]	Odds Ratio
Heterogeneity: Tau ² = Test for overall effect: Test for suboroup diffe Study or Subgroup 1.5.1 Clinical diagnos Martines 2015 Hong 2016 Li 2018 Chang 2019 Qian 2020 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect: 1.5.2 Self-report or IC Staudt 2019 Loiselle 2020 Chamouton 2021 Choi 2021 Kuang 2022 Zeleznik 2023 Lee 2024 Subtotal (95% Cl)	Z = 3.14 (P = 0.002 rences: Chi ² = 2.55 log[Odds Ratio] sis 0.54232429 0.55961579 0.99694864 -0.02020271 0.10436002 0.06; Chi ² = 7.23, d Z = 2.03 (P = 0.04) CD codes 0.37156356 0.05826891 0.47623418 0.06765865 0.0861777 0.19062036 0.01980263 0.00; Chi ² = 9.84, d) . df = 1 (P = 0 <u>SE</u> 0.57141569 0.1695785 0.45669817 0.21728373 0.29749246 f = 4 (P = 0.12 0.20042616 0.03598944 0.16673 0.16668542 0.0700094 0.11290022 0.06977999	0.11). I ² = 6 Weight 0.8% 6.8% 1.3% 4.7% 2.7% 16.2% 2); I ² = 45% 5.3% 20.8% 6.9% 6.9% 16.3% 11.2% 16.4% 83.8%	Odds Ratio IV. Random. 95% Cl 1.72 [0.56, 5.27] 1.75 [1.26, 2.44] 2.71 [1.11, 6.63] 0.98 [0.64, 1.50] 1.11 [0.62, 1.99] 1.43 [1.01, 2.01] 4 1.45 [0.98, 2.15] 1.06 [0.99, 1.14] 1.61 [1.16, 2.23] 1.07 [0.77, 1.48] 1.09 [0.95, 1.25] 1.21 [0.97, 1.51] 1.02 [0.89, 1.17] 1.12 [1.02, 1.21]	Odds Ratio
Heterogeneity: Tau ² = Test for overall effect: Test for suboroup diffe Study or Subgroup 1.5.1 Clinical diagnos Martines 2015 Hong 2016 Li 2018 Chang 2019 Qian 2020 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect: 1.5.2 Self-report or IC Staudt 2019 Loiselle 2020 Chamouton 2021 Choi 2021 Kuang 2022 Zeleznik 2023 Lee 2024 Subtotal (95% Cl) Heterogeneity: Tau ² =	Z = 3.14 (P = 0.002 rences: Chi ² = 2.55 log[Odds Ratio] sis 0.54232429 0.55961579 0.99694864 -0.02020271 0.10436002 0.06; Chi ² = 7.23, d Z = 2.03 (P = 0.04) CD codes 0.37156356 0.05826891 0.47623418 0.06765865 0.0861777 0.19062036 0.01980263 0.00; Chi ² = 9.84, d) . df = 1 (P = 0 <u>SE</u> 0.57141569 0.1695785 0.45669817 0.21728373 0.29749246 f = 4 (P = 0.12 0.20042616 0.03598944 0.16673 0.16668542 0.0700094 0.11290022 0.06977999	0.11). I ² = 6 Weight 0.8% 6.8% 1.3% 4.7% 2.7% 16.2% 2); I ² = 45% 5.3% 20.8% 6.9% 6.9% 16.3% 11.2% 16.4% 83.8%	Odds Ratio IV. Random. 95% Cl 1.72 [0.56, 5.27] 1.75 [1.26, 2.44] 2.71 [1.11, 6.63] 0.98 [0.64, 1.50] 1.11 [0.62, 1.99] 1.43 [1.01, 2.01] 4 1.45 [0.98, 2.15] 1.06 [0.99, 1.14] 1.61 [1.16, 2.23] 1.07 [0.77, 1.48] 1.09 [0.95, 1.25] 1.21 [0.97, 1.51] 1.02 [0.89, 1.17] 1.12 [1.02, 1.21]	Odds Ratio
Heterogeneity: Tau ² = Test for overall effect: Test for suboroup differ Study or Subgroup 1.5.1 Clinical diagnos Martines 2015 Hong 2016 Li 2018 Chang 2019 Qian 2020 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect: 1.5.2 Self-report or IC Staudt 2019 Loiselle 2020 Chamouton 2021 Choi 2021 Kuang 2022 Zeleznik 2023 Lee 2024 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect:	Z = 3.14 (P = 0.002 rences: Chi ² = 2.55 log[Odds Ratio] 0.55961579 0.99694864 -0.02020271 0.10436002 0.06; Chi ² = 7.23, d Z = 2.03 (P = 0.04) CD codes 0.37156356 0.05826891 0.47623418 0.06765865 0.0861777 0.19062036 0.01980263 0.00; Chi ² = 9.84, d Z = 2.50 (P = 0.01)) df = 1 (P = 0 <u>SE</u> 0.57141569 0.1695785 0.45669817 0.21728373 0.29749246 f = 4 (P = 0.12 0.20042616 0.03598944 0.16673 0.16668542 0.0700094 0.11290022 0.06977999 f = 6 (P = 0.12	0.11). ² = 6 Weight 0.8% 6.8% 1.3% 4.7% 2.7% 16.2% 2); ² = 45% 5.3% 20.8% 6.9% 6.9% 16.3% 11.2% 16.4% 83.8% 3); ² = 39% 100.0%	O.8% Odds Ratio IV. Random. 95% Cl 1.72 [0.56, 5.27] 1.75 [1.26, 2.44] 2.71 [1.11, 6.63] 0.98 [0.64, 1.50] 1.11 [0.62, 1.99] 1.43 [1.01, 2.01] 6 1.45 [0.98, 2.15] 1.06 [0.99, 1.14] 1.61 [1.16, 2.23] 1.07 [0.77, 1.48] 1.09 [0.95, 1.25] 1.21 [0.97, 1.51] 1.02 [0.89, 1.17] 1.12 [1.02, 1.21] 6 1.18 [1.06, 1.31]	Odds Ratio

Figure 4. Forest plots for the subgroup analyses of the association between DM and tinnitus. (A) The subgroup analysis according to the proportion of men and (B) The subgroup analysis according to the methods for diagnosis of tinnitus. DM: Diabetes mellitus; CI: Confidence intervals.

Α					Odds Ratio	(Odds Ratio	
· .	Study or Subgroup	log[Odds Ratio]	SE	Weight	IV, Random, 95% Cl	IV, R	andom, 95% Cl	
	1.6.1 Prevalence of tin	nnitus < 25%						
	Hong 2016	0.55961579	0.1695785	6.8%	1.75 [1.26, 2.44]			
	Staudt 2019	0.37156356	0.20042616	5.3%	1.45 [0.98, 2.15]			
	Qian 2020	0.10436002	0.29749246	2.7%	1.11 [0.62, 1.99]			
	Loiselle 2020	0.05826891	0.03598944	20.8%	1.06 [0.99, 1.14]		•	
	Choi 2021	0.06765865	0.16668542	6.9%	1.07 [0.77, 1.48]		- -	
	Zeleznik 2023	0.19062036	0.11290022	11.2%	1.21 [0.97, 1.51]			
	Subtotal (95% CI)			53.7%	1.22 [1.04, 1.43]		•	
	Heterogeneity: Tau ² =	0.02; Chi ² = 11.20,	df = 5 (P = 0.0	05); l² = 55	5%			
	Test for overall effect: 2	Z = 2.40 (P = 0.02)						
	1.6.2 Prevalence of til	nnitus ≥ 25%						
	Martines 2015		0.57141569	0.8%	1.72 [0.56, 5.27]			_
	Li 2018		0.45669817	1.3%	2.71 [1.11, 6.63]			
	Chang 2019	-0.02020271		4.7%	0.98 [0.64, 1.50]			
	Chamouton 2021	0.47623418	0.16673	6.9%	1.61 [1.16, 2.23]			
	Kuang 2022	0.0861777	0.0700094	16.3%	1.09 [0.95, 1.25]		+ - -	
	Lee 2024		0.06977999	16.4%	1.02 [0.89, 1.17]		+	
	Subtotal (95% CI)	5.0.000200		46.3%	1.18 [0.98, 1.41]		◆	
	Heterogeneity: Tau ² =	0.02; Chi ² = 11.20,	df = 5 (P = 0.0					
	Test for overall effect: 2	Z = 1.78 (P = 0.08)	,					
	Total (95% CI)			100.0%	1.18 [1.06, 1.31]		•	
	Heterogeneity: Tau ² =	0.01; Chi ² = 22.40,	df = 11 (P = 0	.02); l ² = 5	51%			<u>+</u>
	Test for overall effect: 2	Z = 3.14 (P = 0.002)			0.2 0.5	5 1 2	5
	Test for subaroup diffe	rences: Chi ² = 0.07	. df = 1 (P = 0	.79). I ² = ()%			
_							Odds Ratio	
					Odds Ratio			
В	Study or Subgroup	log[Odds Ratio]	SE	Weight	Odds Ratio IV, Random, 95% Cl		andom, 95% Cl	
В.	Study or Subgroup 1.7.1 Univariate	log[Odds Ratio]	SE	Weight				
В.					IV, Random, 95% Cl			
В.	1.7.1 Univariate	log[Odds Ratio] 0.37156356 0.0861777		Weight 5.3% 16.3%	IV, Random, 95% Cl 1.45 [0.98, 2.15]			
в	1.7.1 Univariate Staudt 2019	0.37156356 0.0861777	0.20042616	5.3%	IV, Random, 95% Cl			
В.	1.7.1 Univariate Staudt 2019 Kuang 2022	0.37156356 0.0861777 0.19062036	0.20042616 0.0700094	5.3% 16.3%	IV. Random, 95% Cl 1.45 [0.98, 2.15] 1.09 [0.95, 1.25]			
В _	1.7.1 Univariate Staudt 2019 Kuang 2022 Zeleznik 2023	0.37156356 0.0861777 0.19062036	0.20042616 0.0700094 0.11290022	5.3% 16.3% 11.2%	IV. Random, 95% Cl 1.45 [0.98, 2.15] 1.09 [0.95, 1.25] 1.21 [0.97, 1.51]			
в.	1.7.1 Univariate Staudt 2019 Kuang 2022 Zeleznik 2023 Lee 2024	0.37156356 0.0861777 0.19062036 0.01980263	0.20042616 0.0700094 0.11290022 0.06977999	5.3% 16.3% 11.2% 16.4% 49.1%	IV. Random, 95% Cl 1.45 [0.98, 2.15] 1.09 [0.95, 1.25] 1.21 [0.97, 1.51] 1.02 [0.89, 1.17] 1.10 [1.00, 1.22]			
в _	1.7.1 Univariate Staudt 2019 Kuang 2022 Zeleznik 2023 Lee 2024 Subtotal (95% CI)	0.37156356 0.0861777 0.19062036 0.01980263 0.00; Chi ² = 3.78, d	0.20042616 0.0700094 0.11290022 0.06977999	5.3% 16.3% 11.2% 16.4% 49.1%	IV. Random, 95% Cl 1.45 [0.98, 2.15] 1.09 [0.95, 1.25] 1.21 [0.97, 1.51] 1.02 [0.89, 1.17] 1.10 [1.00, 1.22]			
Β	1.7.1 Univariate Staudt 2019 Kuang 2022 Zeleznik 2023 Lee 2024 Subtotal (95% CI) Heterogeneity: Tau ² = 0	0.37156356 0.0861777 0.19062036 0.01980263 0.00; Chi ² = 3.78, d	0.20042616 0.0700094 0.11290022 0.06977999	5.3% 16.3% 11.2% 16.4% 49.1%	IV. Random, 95% Cl 1.45 [0.98, 2.15] 1.09 [0.95, 1.25] 1.21 [0.97, 1.51] 1.02 [0.89, 1.17] 1.10 [1.00, 1.22]			
Β.	1.7.1 Univariate Staudt 2019 Kuang 2022 Zeleznik 2023 Lee 2024 Subtotal (95% CI) Heterogeneity: Tau ² = 1 Test for overall effect: 2	0.37156356 0.0861777 0.19062036 0.01980263 0.00; Chi² = 3.78, d Z = 1.88 (P = 0.06)	0.20042616 0.0700094 0.11290022 0.06977999	5.3% 16.3% 11.2% 16.4% 49.1%	IV. Random, 95% Cl 1.45 [0.98, 2.15] 1.09 [0.95, 1.25] 1.21 [0.97, 1.51] 1.02 [0.89, 1.17] 1.10 [1.00, 1.22]			
Β.	1.7.1 Univariate Staudt 2019 Kuang 2022 Zeleznik 2023 Lee 2024 Subtotal (95% CI) Heterogeneity: Tau ² = 1 Test for overall effect: 2 1.7.2 Multivariate	0.37156356 0.0861777 0.19062036 0.01980263 0.00; Chi² = 3.78, d Z = 1.88 (P = 0.06)	0.20042616 0.0700094 0.11290022 0.06977999 f = 3 (P = 0.29	5.3% 16.3% 11.2% 16.4% 49.1% 9); I ² = 219	IV. Random, 95% Cl 1.45 [0.98, 2.15] 1.09 [0.95, 1.25] 1.21 [0.97, 1.51] 1.02 [0.89, 1.17] 1.10 [1.00, 1.22]			
Β.	1.7.1 Univariate Staudt 2019 Kuang 2022 Zeleznik 2023 Lee 2024 Subtotal (95% CI) Heterogeneity: Tau ² = 1 Test for overall effect: $\frac{1}{2}$ 1.7.2 Multivariate Martines 2015	0.37156356 0.0861777 0.19062036 0.01980263 0.00; Chi ² = 3.78, d Z = 1.88 (P = 0.06) 0.54232429 0.55961579	0.20042616 0.0700094 0.11290022 0.06977999 f = 3 (P = 0.29 0.57141569	5.3% 16.3% 11.2% 16.4% 49.1% 9); I ² = 219	IV. Random, 95% Cl 1.45 [0.98, 2.15] 1.09 [0.95, 1.25] 1.21 [0.97, 1.51] 1.02 [0.89, 1.17] 1.10 [1.00, 1.22] % 1.72 [0.56, 5.27]			
Β.	1.7.1 Univariate Staudt 2019 Kuang 2022 Zeleznik 2023 Lee 2024 Subtotal (95% CI) Heterogeneity: Tau ² = 1 Test for overall effect: $\frac{1}{2}$ 1.7.2 Multivariate Martines 2015 Hong 2016	0.37156356 0.0861777 0.19062036 0.01980263 0.00; Chi ² = 3.78, d Z = 1.88 (P = 0.06) 0.54232429 0.55961579	0.20042616 0.0700094 0.11290022 0.06977999 f = 3 (P = 0.29 0.57141569 0.1695785 0.45669817	5.3% 16.3% 11.2% 16.4% 49.1% 9); I ² = 219 0.8% 6.8%	IV. Random, 95% Cl 1.45 [0.98, 2.15] 1.09 [0.95, 1.25] 1.21 [0.97, 1.51] 1.02 [0.89, 1.17] 1.10 [1.00, 1.22] % 1.72 [0.56, 5.27] 1.75 [1.26, 2.44]			
Β.	1.7.1 Univariate Staudt 2019 Kuang 2022 Zeleznik 2023 Lee 2024 Subtotal (95% CI) Heterogeneity: Tau ² = $($ Test for overall effect: 2 1.7.2 Multivariate Martines 2015 Hong 2016 Li 2018	0.37156356 0.0861777 0.19062036 0.01980263 0.00; Chi ² = 3.78, d Z = 1.88 (P = 0.06) 0.54232429 0.55961579 0.99694864	0.20042616 0.0700094 0.11290022 0.06977999 f = 3 (P = 0.29 0.57141569 0.1695785 0.45669817 0.21728373	5.3% 16.3% 11.2% 16.4% 49.1% 9); I ² = 219 0.8% 6.8% 1.3%	IV. Random, 95% Cl 1.45 [0.98, 2.15] 1.09 [0.95, 1.25] 1.21 [0.97, 1.51] 1.02 [0.89, 1.17] 1.10 [1.00, 1.22] % 1.72 [0.56, 5.27] 1.75 [1.26, 2.44] 2.71 [1.11, 6.63]			
Β.	1.7.1 Univariate Staudt 2019 Kuang 2022 Zeleznik 2023 Lee 2024 Subtotal (95% CI) Heterogeneity: Tau ² = $($ Test for overall effect: 2 1.7.2 Multivariate Martines 2015 Hong 2016 Li 2018 Chang 2019	$\begin{array}{c} 0.37156356\\ 0.0861777\\ 0.19062036\\ 0.01980263\\ \end{array}$ 0.00; Chi ² = 3.78, d Z = 1.88 (P = 0.06) 0.54232429\\ 0.55961579\\ 0.99694864\\ -0.02020271\\ 0.10436002\\ \end{array}	0.20042616 0.0700094 0.11290022 0.06977999 f = 3 (P = 0.29 0.57141569 0.1695785 0.45669817 0.21728373	5.3% 16.3% 11.2% 16.4% 49.1% 9); I ² = 219 0.8% 6.8% 1.3% 4.7%	IV. Random, 95% Cl 1.45 [0.98, 2.15] 1.09 [0.95, 1.25] 1.21 [0.97, 1.51] 1.02 [0.89, 1.17] 1.10 [1.00, 1.22] % 1.72 [0.56, 5.27] 1.75 [1.26, 2.44] 2.71 [1.11, 6.63] 0.98 [0.64, 1.50]			
Β.	1.7.1 Univariate Staudt 2019 Kuang 2022 Zeleznik 2023 Lee 2024 Subtotal (95% CI) Heterogeneity: Tau ² = $($ Test for overall effect: 2 1.7.2 Multivariate Martines 2015 Hong 2016 Li 2018 Chang 2019 Qian 2020	$\begin{array}{c} 0.37156356\\ 0.0861777\\ 0.19062036\\ 0.01980263\\ \end{array}$ 0.00; Chi ² = 3.78, d Z = 1.88 (P = 0.06) 0.54232429\\ 0.55961579\\ 0.99694864\\ -0.02020271\\ 0.10436002\\ \end{array}	0.20042616 0.0700094 0.11290022 0.06977999 f = 3 (P = 0.29 0.57141569 0.1695785 0.45669817 0.21728373 0.29749246	5.3% 16.3% 11.2% 16.4% 49.1% 9); I ² = 219 0.8% 6.8% 1.3% 4.7% 2.7%	IV. Random, 95% Cl 1.45 [0.98, 2.15] 1.09 [0.95, 1.25] 1.21 [0.97, 1.51] 1.02 [0.89, 1.17] 1.10 [1.00, 1.22] % 1.72 [0.56, 5.27] 1.75 [1.26, 2.44] 2.71 [1.11, 6.63] 0.98 [0.64, 1.50] 1.11 [0.62, 1.99]			
Β.	1.7.1 Univariate Staudt 2019 Kuang 2022 Zeleznik 2023 Lee 2024 Subtotal (95% CI) Heterogeneity: Tau ² = 1 Test for overall effect: 2 1.7.2 Multivariate Martines 2015 Hong 2016 Li 2018 Chang 2019 Qian 2020 Loiselle 2020	$\begin{array}{c} 0.37156356\\ 0.0861777\\ 0.19062036\\ 0.01980263\\ \end{array}$ 0.00; Chi ² = 3.78, d Z = 1.88 (P = 0.06) 0.55961579\\ 0.99694864\\ -0.02020271\\ 0.10436002\\ 0.05826891\\ 0.47623418\\ \end{array}	0.20042616 0.0700094 0.11290022 0.06977999 f = 3 (P = 0.29 0.57141569 0.1695785 0.45669817 0.21728373 0.29749246 0.03598944	5.3% 16.3% 11.2% 16.4% 49.1% 9); ² = 219 0.8% 6.8% 1.3% 4.7% 2.7% 20.8%	IV. Random, 95% Cl 1.45 [0.98, 2.15] 1.09 [0.95, 1.25] 1.21 [0.97, 1.51] 1.02 [0.89, 1.17] 1.10 [1.00, 1.22] % 1.72 [0.56, 5.27] 1.75 [1.26, 2.44] 2.71 [1.11, 6.63] 0.98 [0.64, 1.50] 1.11 [0.62, 1.99] 1.06 [0.99, 1.14]			
Β.	1.7.1 Univariate Staudt 2019 Kuang 2022 Zeleznik 2023 Lee 2024 Subtotal (95% Cl) Heterogeneity: Tau ² = 0 Test for overall effect: 2 1.7.2 Multivariate Martines 2015 Hong 2016 Li 2018 Chang 2019 Qian 2020 Loiselle 2020 Chamouton 2021	$\begin{array}{c} 0.37156356\\ 0.0861777\\ 0.19062036\\ 0.01980263\\ \end{array}$ 0.00; Chi ² = 3.78, d Z = 1.88 (P = 0.06) 0.55961579\\ 0.99694864\\ -0.02020271\\ 0.10436002\\ 0.05826891\\ 0.47623418\\ \end{array}	0.20042616 0.0700094 0.11290022 0.06977999 f = 3 (P = 0.29 0.57141569 0.1695785 0.45669817 0.21728373 0.29749246 0.03598944 0.16673	5.3% 16.3% 11.2% 16.4% 49.1% 9); ² = 219 0.8% 6.8% 1.3% 4.7% 2.7% 20.8% 6.9%	IV. Random, 95% Cl 1.45 [0.98, 2.15] 1.09 [0.95, 1.25] 1.21 [0.97, 1.51] 1.02 [0.89, 1.17] 1.10 [1.00, 1.22] % 1.72 [0.56, 5.27] 1.75 [1.26, 2.44] 2.71 [1.11, 6.63] 0.98 [0.64, 1.50] 1.11 [0.62, 1.99] 1.06 [0.99, 1.14] 1.61 [1.16, 2.23]			
Β.	1.7.1 Univariate Staudt 2019 Kuang 2022 Zeleznik 2023 Lee 2024 Subtotal (95% Cl) Heterogeneity: Tau ² = 1 Test for overall effect: 2 1.7.2 Multivariate Martines 2015 Hong 2016 Li 2018 Chang 2019 Qian 2020 Loiselle 2020 Chamouton 2021 Choi 2021 Subtotal (95% Cl) Heterogeneity: Tau ² = 1	$\begin{array}{c} 0.37156356\\ 0.0861777\\ 0.19062036\\ 0.01980263\\ \end{array}$ 0.00; Chi ² = 3.78, d Z = 1.88 (P = 0.06) 0.54232429\\ 0.55961579\\ 0.99694864\\ -0.02020271\\ 0.10436002\\ 0.05826891\\ 0.47623418\\ 0.06765865\\ \end{array}	0.20042616 0.0700094 0.11290022 0.06977999 f = 3 (P = 0.29 0.57141569 0.1695785 0.45669817 0.21728373 0.29749246 0.03598944 0.16673 0.16668542	5.3% 16.3% 11.2% 16.4% 49.1% 9); I ² = 219 0.8% 6.8% 1.3% 4.7% 2.7% 20.8% 6.9% 6.9% 50.9%	IV. Random, 95% Cl 1.45 [0.98, 2.15] 1.09 [0.95, 1.25] 1.21 [0.97, 1.51] 1.02 [0.89, 1.17] 1.10 [1.00, 1.22] % 1.75 [1.26, 2.44] 2.71 [1.11, 6.63] 0.98 [0.64, 1.50] 1.11 [0.62, 1.99] 1.06 [0.99, 1.14] 1.61 [1.16, 2.23] 1.07 [0.77, 1.48] 1.29 [1.05, 1.59]			
Β.	1.7.1 Univariate Staudt 2019 Kuang 2022 Zeleznik 2023 Lee 2024 Subtotal (95% Cl) Heterogeneity: Tau ² = 1 Test for overall effect: 2 1.7.2 Multivariate Martines 2015 Hong 2016 Li 2018 Chang 2019 Qian 2020 Loiselle 2020 Chamouton 2021 Choi 2021 Subtotal (95% Cl) Heterogeneity: Tau ² = 1 Test for overall effect: 2	$\begin{array}{c} 0.37156356\\ 0.0861777\\ 0.19062036\\ 0.01980263\\ \end{array}$ 0.00; Chi ² = 3.78, d Z = 1.88 (P = 0.06) 0.54232429\\ 0.55961579\\ 0.99694864\\ -0.02020271\\ 0.10436002\\ 0.05826891\\ 0.47623418\\ 0.06765865\\ \end{array}	0.20042616 0.0700094 0.11290022 0.06977999 f = 3 (P = 0.29 0.57141569 0.1695785 0.45669817 0.21728373 0.29749246 0.03598944 0.16673 0.16668542	5.3% 16.3% 11.2% 16.4% 49.1% 9); I ² = 219 0.8% 6.8% 1.3% 4.7% 2.7% 20.8% 6.9% 6.9% 50.9% 010); I ² = 6	IV. Random, 95% Cl 1.45 [0.98, 2.15] 1.09 [0.95, 1.25] 1.21 [0.97, 1.51] 1.02 [0.89, 1.17] 1.10 [1.00, 1.22] % 1.75 [1.26, 2.44] 2.71 [1.11, 6.63] 0.98 [0.64, 1.50] 1.11 [0.62, 1.99] 1.06 [0.99, 1.14] 1.61 [1.16, 2.23] 1.07 [0.77, 1.48] 1.29 [1.05, 1.59] \$			
Β.	1.7.1 Univariate Staudt 2019 Kuang 2022 Zeleznik 2023 Lee 2024 Subtotal (95% Cl) Heterogeneity: Tau ² = 1 Test for overall effect: 2 1.7.2 Multivariate Martines 2015 Hong 2016 Li 2018 Chang 2019 Qian 2020 Loiselle 2020 Chamouton 2021 Choi 2021 Subtotal (95% Cl) Heterogeneity: Tau ² = 1 Test for overall effect: 2	$\begin{array}{c} 0.37156356\\ 0.0861777\\ 0.19062036\\ 0.01980263\\\\ 0.00; \ Chi^2 = 3.78, \ d\\\\ Z = 1.88 \ (P = 0.06)\\\\ 0.54232429\\ 0.55961579\\ 0.99694864\\ -0.02020271\\ 0.10436002\\ 0.05826891\\ 0.47623418\\ 0.06765865\\\\ 0.04; \ Chi^2 = 18.58,\\\\ Z = 2.39 \ (P = 0.02)\\\\ \end{array}$	0.20042616 0.0700094 0.11290022 0.06977999 f = 3 (P = 0.29 0.57141569 0.1695785 0.45669817 0.21728373 0.29749246 0.03598944 0.16673 0.16668542 df = 7 (P = 0.0	5.3% 16.3% 11.2% 16.4% 49.1% 9); I ² = 219 0.8% 6.8% 1.3% 4.7% 2.7% 20.8% 6.9% 6.9% 50.9% 50.9% 010); I ² = 6	IV. Random, 95% Cl 1.45 [0.98, 2.15] 1.09 [0.95, 1.25] 1.21 [0.97, 1.51] 1.02 [0.89, 1.17] 1.10 [1.00, 1.22] % 1.75 [1.26, 2.44] 2.71 [1.11, 6.63] 0.98 [0.64, 1.50] 1.11 [0.62, 1.99] 1.06 [0.99, 1.14] 1.61 [1.16, 2.23] 1.07 [0.77, 1.48] 1.29 [1.05, 1.59] S2% 1.18 [1.06, 1.31]			
в.	1.7.1 Univariate Staudt 2019 Kuang 2022 Zeleznik 2023 Lee 2024 Subtotal (95% Cl) Heterogeneity: Tau ² = 1 Test for overall effect: 2 1.7.2 Multivariate Martines 2015 Hong 2016 Li 2018 Chang 2019 Qian 2020 Loiselle 2020 Chamouton 2021 Choi 2021 Subtotal (95% Cl) Heterogeneity: Tau ² = 1 Total (95% Cl)	$\begin{array}{c} 0.37156356\\ 0.0861777\\ 0.19062036\\ 0.01980263\\\\ 0.00; \ Chi^2=3.78, \ d\\\\ Z=1.88\ (P=0.06)\\\\ 0.54232429\\ 0.55961579\\ 0.99694864\\ -0.02020271\\ 0.10436002\\ 0.05826891\\ 0.47623418\\ 0.06765865\\\\ 0.04; \ Chi^2=18.58,\\\\ Z=2.39\ (P=0.02)\\\\ 0.01; \ Chi^2=22.40,\\ \end{array}$	0.20042616 0.0700094 0.11290022 0.06977999 f = 3 (P = 0.29 0.57141569 0.1695785 0.45669817 0.21728373 0.29749246 0.03598944 0.16673 0.16668542 df = 7 (P = 0.0 df = 11 (P = 0.0	5.3% 16.3% 11.2% 16.4% 49.1% 9); I ² = 219 0.8% 6.8% 1.3% 4.7% 2.7% 20.8% 6.9% 6.9% 50.9% 50.9% 010); I ² = 6	IV. Random, 95% Cl 1.45 [0.98, 2.15] 1.09 [0.95, 1.25] 1.21 [0.97, 1.51] 1.02 [0.89, 1.17] 1.10 [1.00, 1.22] % 1.75 [1.26, 2.44] 2.71 [1.11, 6.63] 0.98 [0.64, 1.50] 1.11 [0.62, 1.99] 1.06 [0.99, 1.14] 1.61 [1.16, 2.23] 1.07 [0.77, 1.48] 1.29 [1.05, 1.59] S2% 1.18 [1.06, 1.31]		andom. 95% Cl	5
Β.	1.7.1 Univariate Staudt 2019 Kuang 2022 Zeleznik 2023 Lee 2024 Subtotal (95% Cl) Heterogeneity: Tau ² = 1 Test for overall effect: 2 1.7.2 Multivariate Martines 2015 Hong 2016 Li 2018 Chang 2019 Qian 2020 Loiselle 2020 Chamouton 2021 Choi 2021 Subtotal (95% Cl) Heterogeneity: Tau ² = 1 Test for overall effect: 2	$\begin{array}{c} 0.37156356\\ 0.0861777\\ 0.19062036\\ 0.01980263\\\\ 0.00; Chi^2 = 3.78, d\\\\ Z = 1.88 \ (P = 0.06)\\\\ 0.54232429\\ 0.55961579\\ 0.99694864\\ -0.02020271\\ 0.10436002\\ 0.05826891\\ 0.47623418\\ 0.06765865\\\\ 0.04; Chi^2 = 18.58,\\\\ Z = 2.39 \ (P = 0.02)\\\\ 0.01; Chi^2 = 22.40,\\\\ Z = 3.14 \ (P = 0.002\\\\ \end{array}$	0.20042616 0.0700094 0.11290022 0.06977999 f = 3 (P = 0.29 0.57141569 0.1695785 0.45669817 0.21728373 0.29749246 0.03598944 0.16673 0.16668542 df = 7 (P = 0.0 df = 11 (P = 0)	5.3% 16.3% 11.2% 16.4% 49.1% 9); ² = 219 0.8% 6.8% 1.3% 4.7% 2.7% 20.8% 6.9% 50.9% 50.9% 50.9% 010); ² = 6 100.0%	IV. Random, 95% Cl 1.45 [0.98, 2.15] 1.09 [0.95, 1.25] 1.21 [0.97, 1.51] 1.02 [0.89, 1.17] 1.10 [1.00, 1.22] % 1.75 [1.26, 2.44] 2.71 [1.11, 6.63] 0.98 [0.64, 1.50] 1.11 [0.62, 1.99] 1.06 [0.99, 1.14] 1.61 [1.16, 2.23] 1.07 [0.77, 1.48] 1.29 [1.05, 1.59] 52% 1.18 [1.06, 1.31] 51%		andom. 95% Cl	5

Figure 5. Forest plots for the subgroup analyses of the association between DM and tinnitus. (A) The subgroup analysis according to the prevalence of tinnitus in each study and (B) The subgroup analysis according to the analytic model for estimating the association between DM and tinnitus. DM: Diabetes mellitus; CI: Confidence intervals.




Figure 6. Funnel plots for the publication bias underlying the meta-analysis of the association between DM and tinnitus. DM: Diabetes mellitus.

studies in meta-analyses, as they often lack sufficient statistical power to detect clinically meaningful differences [30]. Furthermore, the use of a random-effects model accounts for between-study variability, bolstering the validity of the pooled results. The clinical implications of these findings are significant, underscoring the need for heightened awareness among healthcare providers about the potential association between DM and tinnitus. Patients with DM should be monitored for auditory symptoms, as early identification of tinnitus in this population could prompt timely interventions to manage both conditions more effectively [47, 48]. Tinnitus, which can adversely impact quality of life by contributing to hearing difficulties, sleep disturbances, and psychological stress, should be recognized as an important comorbidity in individuals with DM. In particular, those with DM should prioritize sleep quality and duration, as poor sleep has been associated with elevated levels of fibroblast growth factor (FGF), a factor that can exacerbate diabetic complications [49]. The interplay between sleep disturbances and diabetes-related complications is mediated by mechanisms, such as increased oxidative stress, dysregulation of appetite-regulating hormones, and heightened sympathetic nervous system activity [50]. By highlighting these interconnections, the findings provide a deeper understanding of how managing sleep may alleviate tinnitus symptoms and improve overall metabolic health in individuals with DM. Additionally, the meta-analysis suggests that controlling blood glucose levels and addressing DM-related complications could reduce the risk or severity of tinnitus. Nonetheless, further research is needed to confirm these hypotheses and translate them into clinical practice.

Future research should prioritize prospective cohort studies to investigate the temporal relationship between DM and tinnitus, with a strong focus on controlling for potential confounders, such as age, sex, lifestyle factors, and comorbid conditions. Additionally, studies that delve into the pathophysiological mechanisms connecting DM and tinnitus are necessary to illuminate the causal pathways involved. Exploring the roles of different types of DM, particularly the distinct contributions of type 1 and type 2 diabetes, could further clarify these mechanisms. Furthermore, evaluating interventions aimed at improving glycemic control and mitigating DM-related complications may reveal their potential to prevent or reduce tinnitus in diabetic patients [36]. Lastly, the development of standardized diagnostic criteria for both DM and tinnitus in future studies would enhance result comparability and strengthen the evidence base for this association.

Conclusion

In conclusion, this meta-analysis demonstrates a significant association between DM and tinnitus, revealing an 18% increased likelihood of tinnitus in individuals with DM. The consistency of results across sensitivity and subgroup analyses highlights the robustness of these findings. Although the precise mechanisms underlying this association are not yet fully understood, factors, such as vascular damage, inflammation, oxidative stress, and metabolic dysregulation are likely contributors to the development of tinnitus in individuals with DM. These findings carry potential clinical implications for the management of patients with DM. However, further research is needed to establish a causal relationship and investigate potential interventions to reduce the risk of tinnitus in this population.

Conflicts of interest: Authors declare no conflicts of interest.

Funding: Authors received no funding for this study.

Data availability: All the data generated during the study was within the manuscript and the supplemental materials.

Submitted: 10 November 2024 Accepted: 08 December 2024 Published online: 20 January 2025

References

- Jarach CM, Lugo A, Scala M, van den Brandt PA, Cederroth CR, Odone A, et al. Global prevalence and incidence of tinnitus: a systematic review and meta-analysis. JAMA Neurol 2022;79(9):888–900. https://doi.org/10.1001/jamaneurol.2022.2189.
- [2] Langguth B, Kleinjung T, Schlee W, Vanneste S, De Ridder D. Tinnitus guidelines and their evidence base. J Clin Med 2023;12(9):3087. https://doi.org/10.3390/jcm12093087.
- [3] Bhatt JM, Lin HW, Bhattacharyya N. Prevalence, severity, exposures, and treatment patterns of tinnitus in the United States. JAMA Otolaryngol Head Neck Surg 2016;142(10):959–65. https://doi.org/10. 1001/jamaoto.2016.1700.
- [4] Hackenberg B, Döge J, O'Brien K, Bohnert A, Lackner KJ, Beutel ME, et al. Tinnitus and its relation to depression, anxiety, and stress—a population-based cohort study. J Clin Med 2023;12(3):1169. https://doi. org/10.3390/jcm12031169.
- [5] Oosterloo BC, de Feijter M, Croll PH, Baatenburg de Jong RJ, Luik AI, Goedegebure A. Cross-sectional and longitudinal associations between tinnitus and mental health in a population-based sample of middle-aged and elderly persons. JAMA Otolaryngol Head Neck Surg 2021;147(8):708–16. https://doi.org/10.1001/jamaoto.2021.1049.
- Beukes EW, Ulep AJ, Andersson G, Manchaiah V. The effects of tinnitus on significant others. J Clin Med 2022;11(5):1393. https://doi.org/10. 3390/jcm11051393.
- [7] Demoen S, Cardon E, Jacquemin L, Timmermans A, Van Rompaey V, Gilles A, et al. Health-related quality of life in subjective, chronic tinnitus patients: a scoping review. J Assoc Res Otolaryngol 2024;25(2):103– 29. https://doi.org/10.1007/s10162-024-00926-5.

- [8] Haider HF, Bojić T, Ribeiro SF, Paço J, Hall DA, Szczepek AJ. Pathophysiology of subjective tinnitus: triggers and maintenance. Front Neurosci 2018;12:866. https://doi.org/10.3389/fnins.2018.00866.
- [9] Tsang BKT, Collins GG, Anderson S, Westcott M. Tinnitus update: what can be done for the ringing? Intern Med J 2024;54(7):1066-76. https:// doi.org/10.1111/imj.16414.
- [10] Goderie T, van Wier MF, Lissenberg-Witte BI, Merkus P, Smits C, Leemans CR, et al. Factors associated with the development of tinnitus and with the degree of annoyance caused by newly developed tinnitus. Ear Hear 2022;43(6):1807–15. https://doi.org/10.1097/AUD. 000000000001250.
- [11] Jannike Heyerdahl-Larsen A, Bo E, Bente O, Laila AH, Magnar J, Norun Hjertager K. Tinnitus and cardiovascular disease: the population-based TromsÃ, Study (2015-2016). BMJ Public Health 2024;2(2):e000621. https://doi.org/10.1136/bmjph-2023-000621.
- [12] Kumar P, Singh NK, Apeksha K, Ghosh V, Kumar RR, Kumar Muthaiah B. Auditory and vestibular functioning in individuals with type-2 diabetes mellitus: a systematic review. Int Arch Otorhinolaryngol 2022;26(2):e281-e8. https://doi.org/10.1055/s-0041-1726041.
- [13] Deng Y, Chen S, Hu J. Diabetes mellitus and hearing loss. Mol Med 2023;29(1):141. https://doi.org/10.1186/s10020-023-00737-z.
- [14] Shi TF, Zhou Z, Jiang WJ, Huang TL, Si JQ, Li L. Hyperglycemiainduced oxidative stress exacerbates mitochondrial apoptosis damage to cochlear stria vascularis pericytes via the ROS-mediated Bcl-2/CytC/AIF pathway. Redox Rep 2024;29(1):2382943. https://doi.org/ 10.1080/13510002.2024.2382943.
- [15] Galiero R, Caturano A, Vetrano E, Beccia D, Brin C, Alfano M, et al. Peripheral neuropathy in diabetes mellitus: pathogenetic mechanisms and diagnostic options. Int J Mol Sci 2023;24(4):3554. https://doi.org/ 10.3390/ijms24043554.
- [16] Martines F, Sireci F, Cannizzaro E, Costanzo R, Martines E, Mucia M, et al. Clinical observations and risk factors for tinnitus in a Sicilian cohort. Eur Arch Otorhinolaryngol 2015;272(10):2719–29. https://doi. org/10.1007/s00405-014-3275-0.
- [17] Hong ZJ, Liu XL, Liu QG. The investigation and analysis of the tinnitus in 1 596 cases of physical examinees. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2016;30(19):1525–8. https://doi.org/10.13201/j.issn. 1001-1781.2016.19.006.
- [18] Li J, Zhang Y, Fu X, Bi J, Li Y, Liu B, et al. Alteration of auditory function in type 2 diabetic and pre-diabetic patients. Acta Otolaryngol 2018;138(6):542-7. https://doi.org/10.1080/00016489. 2017.1422084.
- [19] Chang NC, Dai CY, Lin WY, Yang HL, Wang HM, Chien CY, et al. Prevalence of persistent tinnitus and dizziness in an elderly population in southern Taiwan. J Int Adv Otol 2019;15(1):99–105. https://doi.org/10. 5152/iao.2019.6257.
- [20] Staudt AM, Whitworth KW, Chien LC, Whitehead LW, Gimeno Ruiz de Porras D. Association of organic solvents and occupational noise on hearing loss and tinnitus among adults in the U.S., 1999-2004. Int Arch Occup Environ Health 2019;92(3):403–13. https://doi.org/10. 1007/s00420-019-01419-2.
- [21] Loiselle AR, Neustaeter A, de Kleine E, van Dijk P, Jansonius NM. Associations between tinnitus and glaucoma suggest a common mechanism: a clinical and population-based study. Hear Res 2020;386:107862. https://doi.org/10.1016/j.heares.2019.107862.
- [22] Qian ZJ, Alyono JC. An association between marijuana use and tinnitus. Am J Otolaryngol 2020;41(1):102314. https://doi.org/10.1016/j.amjoto. 2019.102314.
- [23] Chamouton CS, Nakamura HY. Profile and prevalence of people with tinnitus: a health survey. Codas 2021;33(6):e20200293. https://doi. org/10.1590/2317-1782/20202020293.
- [24] Choi J, Lee CH, Kim SY. Association of tinnitus with depression in a normal hearing population. Medicina (Kaunas) 2021;57(2):114. https:// doi.org/10.3390/medicina57020114.
- [25] Kuang TM, Xirasagar S, Cheng YF, Kuo NW, Lin HC. Association of primary open-angle glaucoma with tinnitus: a nationwide population-based study. J Glaucoma 2022;31(4):224–7. https://doi.org/ 10.1097/IJG.00000000002001.
- [26] Zeleznik OA, Welling DB, Stankovic K, Frueh L, Balasubramanian R, Curhan GC, et al. Association of plasma metabolomic biomarkers with persistent tinnitus: a population-based case-control study. JAMA Otolaryngol Head Neck Surg 2023;149(5):404–15. https://doi.org/10.1001/ jamaoto.2023.0052.

- [27] Lee HJ, Lee DC, Kim CO. The association between serum lipid levels and tinnitus prevalence and severity in Korean elderly: a nationwide population-based cross-sectional study. Yonsei Med J 2024;65(3):156– 62. https://doi.org/10.3349/ymj.2022.0626.
- [28] Brooke BS, Schwartz TA, Pawlik TM. MOOSE reporting guidelines for meta-analyses of observational studies. JAMA Surg 2021;156(8):787–8. https://doi.org/10.1001/jamasurg.2021.0522.
- [29] Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al. Cochrane handbook for systematic reviews of interventions version 6.2. The Cochrane Collaboration [Internet]. 2021: Available from: https://www.training.cochrane.org/handbook.
- [30] Turner RM, Bird SM, Higgins JP. The impact of study size on meta-analyses: examination of underpowered studies in Cochrane reviews. PLoS One 2013;8(3):e59202. https://doi.org/10.1371/journal. pone.0059202.
- [31] Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [Internet]. 2010: Available from: http://www.ohri.ca/programs/clinical/_epidemiology/oxford.asp.
- [32] Higgins JP, Thompson SG. Quantifying heterogeneity in a metaanalysis. Stat Med 2002;21(11):1539-58. https://doi.org/10.1002/sim. 1186.
- [33] Patsopoulos NA, Evangelou E, Ioannidis JP. Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. Int J Epidemiol 2008;37(5):1148–57. https:// doi.org/10.1093/ije/dyn065.
- [34] Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34. https://doi.org/10.1136/bmj.315.7109.629.
- [35] Samocha-Bonet D, Wu B, Ryugo DK. Diabetes mellitus and hearing loss: a review. Ageing Res Rev 2021;71:101423. https://doi.org/10.1016/j.arr. 2021.101423.
- [36] Mittal R, Keith G, Lacey M, Lemos JRN, Mittal J, Assayed A, et al. Diabetes mellitus, hearing loss, and therapeutic interventions: a systematic review of insights from preclinical animal models. PLoS One 2024;19(7):e0305617. https://doi.org/10.1371/journal.pone.0305617.
- [37] Xipeng L, Ruiyu L, Meng L, Yanzhuo Z, Kaosan G, Liping W. Effects of diabetes on hearing and cochlear structures. J Otol 2013;8(2):82–7. https://doi.org/10.1016/S1672-2930(13)50017-1.
- [38] Kaltenbach JA. The dorsal cochlear nucleus as a contributor to tinnitus: mechanisms underlying the induction of hyperactivity. Prog Brain Res 2007;166:89–106. https://doi.org/10.1016/S0079-6123(07)66009-9.
- [39] Tzounopoulos T. Mechanisms of synaptic plasticity in the dorsal cochlear nucleus: plasticity-induced changes that could underlie tinnitus. Am J Audiol 2008;17(2):S170–5. https://doi.org/10.1044/1059-0889(2008/07-0030).
- [40] Galazyuk AV, Longenecker RJ, Voytenko SV, Kristaponyte I, Nelson GL. Residual inhibition: from the putative mechanisms to potential tinnitus treatment. Hear Res 2019;375:1–13. https://doi.org/ 10.1016/j.heares.2019.01.022.
- [41] Celik M, Koyuncu İ. A comprehensive study of oxidative stress in tinnitus patients. Indian J Otolaryngol Head Neck Surg 2018;70(4):521– 6. https://doi.org/10.1007/s12070-018-1464-7.
- [42] Mennink LM, Aalbers MW, van Dijk P, van Dijk JMC. The role of inflammation in tinnitus: a systematic review and meta-analysis. J. Clin. Med. 2022;11(4):1000. https://doi.org/10.3390/jcm11041000.
- [43] Lee J, Yun JS, Ko SH. Advanced glycation end products and their effect on vascular complications in type 2 diabetes mellitus. Nutrients 2022;14(15):3086. https://doi.org/10.3390/nu14153086.
- [44] Niihata K, Takahashi S, Kurita N, Yajima N, Omae K, Fukuma S, et al. Association between accumulation of advanced glycation end-products and hearing impairment in community-dwelling older people: a cross-sectional Sukagawa study. J Am Med Dir Assoc 2018;19(3):235–9e1. https://doi.org/10.1016/j.jamda.2017.09.008.
- [45] Al-Sofiani M, MacLeod S, Ghanim H, Stecker N, Hall J, Lippes H. Type 1 diabetes and hearing loss: audiometric assessment and measurement of circulating levels of soluble receptor for advanced glycation end products. Diabetes Metab Res Rev 2020;36(6):e3312. https://doi.org/ 10.1002/dmrr.3312.
- [46] Valentine J, Pigott T, Rothstein H. How many studies do you need? a primer on statistical power for meta-analysis. J Educ Behav Stat 2010;35:215-47. https://doi.org/10.3102/1076998609346961.

Biomolecules & Biomedicine

- [47] Spankovich C, Yerraguntla K. Evaluation and management of patients with diabetes and hearing loss. Semin Hear 2019;40(4):308–14. https://doi.org/10.1055/s-0039-1697644.
- [48] Malucelli DA, Malucelli FJ, Fonseca VR, Zeigeboim B, Ribas A, Trotta F, et al. Hearing loss prevalence in patients with diabetes mellitus type 1. Braz J Otorhinolaryngol 2012;78(3):105–15. https://doi.org/10.1590/ S1808-86942012000300018.
- [49] Surani S, Brito V, Surani A, Ghamande S. Effect of diabetes mellitus on sleep quality. World J Diabetes 2015;6(6):868-73. https://doi.org/ 10.4239/wjd.v6.i6.868.
- [50] Koufakis T, Maltese G, Popovic DS, Kotsa K. The importance of sleep quality, quantity, and chronotype in the management of diabetes: is it time to wake up? J Diabetes 2022;14(9):633–4. https://doi.org/10.1111/ 1753-0407.13313.

Related articles

1. Ultrasonographic abdominal adipose tissue thickness for the prediction of gestational diabetes mellitus: A meta-analysis

Shuhong Hou et al., Biomol Biomed, 2023

2. Association between serum galectin-3 and chronic obstructive pulmonary disease: A meta-analysis

Xiangyu Zhao et al., Biomol Biomed, 2024

3. Serum copeptin in women with gestational diabetes mellitus: A meta-analysis

Yuanqi He et al., Biomol Biomed, 2024

Supplemental data

PubMed (n = 249)

("diabetes mellitus" [MeSH] OR "diabetes" OR "diabetic" OR "type 2 diabetes" OR "T2D" OR "T2DM" OR "type 1 diabetes" OR "T1D" OR "T1DM") AND ("tinnitus" [MeSH] OR "tinnitus")

Embase (n = 562)

("diabetes mellitus"/exp OR "diabetes" OR "diabetic" OR "type 2 diabetes" OR "T2D" OR "T2DM" OR "type 1 diabetes" OR "T1D" OR "T1DM") AND ("tinnitus"/exp OR "tinnitus")

Web of Science (n = 232)

TS= ("diabetic" OR "diabetes" OR "diabetes mellitus" OR "type 2 diabetes" OR "T2D" OR "T2DM" OR "type 1 diabetes" OR "T1D" OR "T1DM") AND TS = ("tinnitus")